@phdthesis{Moriabadi2002, author = {Moriabadi, Neville Fairdoon}, title = {Der Einfluß von Virusinfektion und Impfung auf autoreaktive T-Lymphozyten bei der Multiplen Sklerose}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-5859}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2002}, abstract = {In der sogenannten ViMS-Studie, bei der MS-Patienten und gesunde Kontrollpersonen mit einer Influenza-Spaltvakzine geimpft und f{\"u}r einen zum Teil viermonatigen Zeitraum im Verlauf nachbeobachtet wurden, ergab sich weder mit dem sensitiven IFNg-ELISPOT noch mit der quantitativen RT-PCR ein Anhalt f{\"u}r erh{\"o}hte Autoimmunreaktivit{\"a}t gegen die zwei untersuchten Myelin-Antigene MBP und MOG. Im Gegensatz dazu konnten mit dem IFNg-ELISPOT-Assay bei einigen gesunden Spendern und MS-Patienten nach nat{\"u}rlichen Atemwegsinfektionen eine erh{\"o}hte Frequenz autoreaktiver MBP-spezifischer T-Lymphozyten beobachtet werden. Im zweiten Teil dieser Arbeit konnten durch Zellkulturinfektionen mit Influenzavirus oder HHV-6 weder an Prim{\"a}rzellkulturen noch in einem etablierten in vitro-Modell f{\"u}r MS-Autoimmunit{\"a}t an MBP-spezifischen T-Zellen eine immunstimulierende Wirkung gezeigt werden. Bei niedrigen Infektionsdosen kam es zur Proliferation einer wahrscheinlich virus-spezifischen Zellpopulation, bei h{\"o}heren Dosen wurde dieser Effekt durch die bekannte Immunsuppression der in vitro-Infektion mit HHV-6 {\"u}bertroffen. In einer umfassenden Untersuchung von Serumproben von gesunden Spendern und MS-Patienten in unterschiedlichen Krankheitsphasen wurden trotz sensitiver Nachweismethoden keine erh{\"o}hten Antik{\"o}rper-Titer (IgG/IgM) gegen HHV-6 oder HHV-6-DNA nachgewiesen, woraus geschlossen werden darf, daß die untersuchten Viren keine intrinsische Pathogenit{\"a}t f{\"u}r die Entstehung von Autoimmunit{\"a}t bei der MS aufweisen. Im Vergleich zu der Kontrollgruppe erh{\"o}hte Anti-HHV-6-IgG-Titer bei PTX-behandelten MS-Patienten lassen sich als m{\"o}gliches Epiph{\"a}nomen durch die immun-modulatorische (Th2-vermittelte) Wirkung des Medikaments deuten. In Zusammenschau aller Ergebnisse dieser Arbeit lassen sich die anfangs angedeuteten Modelle einer virusvermittelten Autoimmunpathogenese der MS nicht eindeutig ein-ordnen. Die Ergebnisse der ViMS-Studie, unterst{\"u}tzt durch zahlreiche Untersuchungen anderer Gruppen, weisen in Bezug auf Schubausl{\"o}sung oder Verschlechterung auf einen generellen immunaktivierenden Mechanismus im Sinne einer unspezifischen Begleitreaktion durch Infektion aber nicht durch Influenzaschutzimpfung hin. Dabei spielt wohl nicht eine einzelne Virusinfektion die maßgebliche Rolle in einem schon auf immunologischer Ebene recht komplexen Netzwerk, sondern k{\"o}nnen prinzipiell verschiedene (beliebige) Viren zum Anstoßen einer Autoimmunkaskade beitragen, wenn sie auf einen konstitutionell oder tempor{\"a}r empf{\"a}nglichen Wirtsorganismus treffen. Dies ist auch vom Infektionsort und -milieu abh{\"a}ngig. Bei der vorliegenden Multifaktorialit{\"a}t und Heterogenit{\"a}t der Subpopulatio-nen sind monolineare Erkl{\"a}rungsans{\"a}tze bislang zum Scheitern verurteilt gewesen. Aber aus dem Fehlen eines Beweises kann nicht der Beweis f{\"u}r das Fehlen eines Zusammen-hangs zwischen Virusinfektionen und Autoimmunreaktionen geschlossen werden.}, language = {de} } @phdthesis{Kneitz2004, author = {Kneitz, Ralf-Herbert}, title = {Untersuchung der Avidit{\"a}t von virusspezifischen Antik{\"o}rpern in Serum und Liquor bei Patienten mit Virusenzephalitiden und Multipler Sklerose}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-13118}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2004}, abstract = {Es wurden Avidit{\"a}ten von IgG-Antik{\"o}rper gegen neurotope Viren bei Patienten mit Subakuter Sklerosierender Panenzephalitis (SSPE), Varizella-Zoster-Virus-(VZV-) Infektion mit neurologischen Komplikationen, Multipler Sklerose (MS) und mit nichtentz{\"u}ndlichen, psychiatrischen Hirnerkrankungen untersucht. Es galt insbesondere f{\"u}r Masernvirus- und VZV-Antik{\"o}rper herauszufinden, ob es in gleichzeitig entnommenen Serum- und Liquorproben bei Patienten mit oben genannten Erkrankungen eine signifikante Differenz der Avidit{\"a}ten in Serum und Liquor gibt. Nach Evaluation einer Avidit{\"a}tsbestimmung von VZV-IgG-Antik{\"o}rpern wurden in insgesamt 71 Serum-Liquor-Paaren von Patienten mit oben genannten Krankheiten die Avidit{\"a}ten der IgG-Antik{\"o}rper erhoben. Bei zw{\"o}lf Serum-Liquor-Paaren von sechs SSPE-Patienten sind ausschließlich hochavide masernspezifische Antik{\"o}rper mit mittleren Avidit{\"a}ten von jeweils rund 60\% in Serum und Liquor entdeckt worden. In 28 Serum-Liquor-Paaren von zw{\"o}lf Patienten mit Varizella-Zoster-Virus-Infektion haben sich ebenfalls ausnahmslos hochavide VZV-spezifische Immunglobuline dargestellt. Die Avidit{\"a}tsindices betragen im Mittel 52\% im Serum und 55\% im Liquor. Aus einem Kontrollkollektiv von 18 psychiatrisch erkrankten Patienten mit jeweils einem Serum-Liquor-Paar sind neun Paare auf VZV-spezifische und 14 auf masernspezifische Avidit{\"a}t untersucht worden. Die VZV-Antik{\"o}rper weisen eine Avidit{\"a}t von rund 61\% in Serum und Liquor auf. Die der Masernvirusantik{\"o}rper betr{\"a}gt 55\% in Serum und Liquor. Von den 29 Serum-Liquor-Paaren von Patienten mit Multipler Sklerose sind 15 Paare auf VZV-spezifische und 19 auf masernspezifische Avidit{\"a}t untersucht worden. Die VZV-Antik{\"o}rper weisen eine Serumavidit{\"a}t von 53\% und eine Liquoravidit{\"a}t von 54\% auf. Die der Masernvirusantik{\"o}rper betr{\"a}gt 53\% im Serum und 57\% im Liquor. Das Spektrum der Avidit{\"a}ten ist deutlich weiter gestreut als in den anderen Krankheitskollektiven. W{\"a}hrend dort s{\"a}mtliche Avidit{\"a}ten im hochaviden Bereich liegen, sind die Antik{\"o}rper bei den MS-Patienten sowohl hoch- als auch niedrigavide. Im Schnitt liegen hohe Avidit{\"a}ten bei mehr als der H{\"a}lfte der MS-Patienten vor. Der direkte statistische Vergleich der Avidit{\"a}ten der einzelnen Serum- und Liquorkollektive zeigt keinen signifikanten Unterschied. Schließlich ist noch die Avidit{\"a}t des Serum von der des Liquor eines jeweiligen Paares subtrahiert worden. Außer bei den Patienten mit Multipler Sklerose sind diese Differenzbetr{\"a}ge bei den {\"u}brigen Patienten kleiner als 10\%. Bei einem Teil der MS-Patienten sind die Differenzen in beiden untersuchten Spezifit{\"a}ten gr{\"o}ßer als 10\%. 11\% der MS-Patienten mit VZV-Antik{\"o}rpern hat eine Avidit{\"a}tsdifferenz von mehr als 11\%. Bei 35\% der MS-Patienten mit Masernvirusantik{\"o}rpern ist die Differenz gr{\"o}ßer als 10\%. Bei Patienten, die diese Differenz aufweisen, liegt in jedem Fall eine Multiple Sklerose vor, d.h. die Spezifit{\"a}t betr{\"a}gt 100\%. Statistisch unterscheiden sich die Avidit{\"a}tsdifferenz der MS-Serum-Liquor-Paare signifikant von den {\"u}brigen Kollektiven. Anhand dieses Ergebnisses kann festgestellt werden, dass Differenzen von weniger als 10\% gleiche, Differenzen dar{\"u}ber signifikant unterschiedliche Avidit{\"a}t bedeuten. Diese Erkenntnis bietet einen neuen Ansatz f{\"u}r spezielle Fragestellungen in der Differentialdiagnostik neurologischer Erkrankungen mit intrathekaler, virusspezifischer Antik{\"o}rperproduktion. Serologisch k{\"o}nnte z.B. die Diagnose bei Patienten gefestigt werden, bei denen die Differenzierung zwischen Multipler Sklerose und neurologisch komplizierter Virusinfektion schwierig ist. Allerdings ist die Sensivit{\"a}t mit 11\% f{\"u}r die VZV-Antik{\"o}rper und 35\% f{\"u}r die Masernantik{\"o}rper recht gering. Diese statistisch signifikanten Unterschiede der Differenzen bei der Multiplen Sklerose k{\"o}nnten daher r{\"u}hren, dass intrathekale B-Lymphozyten ohne Einfluss erregerspezifischer Antigene unabh{\"a}ngig von den B-Zellen im Blut ihre Antik{\"o}rper synthetisieren. Das kann zu unterschiedlichen Avidit{\"a}ten in Liquores verglichen mit den Seren von Patienten mit Multipler Sklerose f{\"u}hren. Dagegen sind bei den Virusinfektionen die Antigene in beiden Kompartimenten pr{\"a}sent, weswegen die Antik{\"o}rper sowohl im Serum als auch im Liquor optimal reifen k{\"o}nnen. Das f{\"u}hrt zu hohen, nicht signifikant unterschiedlichen Avidit{\"a}ten.}, language = {de} } @phdthesis{GiraldoVelasquez2004, author = {Giraldo Vel{\´a}squez, Kathrin Christine}, title = {Krankheitsursachen-Vorstellungen von Multiple-Sklerose-Patienten}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-16689}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2004}, abstract = {In einer Querschnitt- und einer L{\"a}ngsschnittuntersuchung an insgesamt 95 Multiple Sklerose Patienten wurden in einem semistrukturierten Interview Krankheitsursachen-Vorstellungen (KUV) erfragt. Mit dem BDI wurde die Depressivit{\"a}t erfasst. Im L{\"a}ngsschnitt wurden 24 neu-diagnostizierte Patienten zu drei Zeitpunkten befragt: Gleich im Anschluss (max. 24 Stunden) an die Diagnoseer{\"o}ffnung, nach 6 Wochen und nach 6 Monaten. Etwa die H{\"a}lfte aller Patienten {\"a}ußerten subjektive Ursachenvorstellungen zu ihrer Erkrankung. In der L{\"a}ngsschnittstudie zeigte sich eine Zunahme der Patienten mit Krankheitsursachen-Vorstellungen, die nach sechs Monaten ebenfalls 50\% erreichten. Inhaltlich konnten zw{\"o}lf Hauptthemen herausgearbeitet werden: Umweltfaktoren, Veranlagung, Strafe, somatische Vorerkrankung, psychische Erkrankung, Schwangerschaft, {\"U}beranstrengung, St{\"o}rung des Immunsystems, labile Pers{\"o}nlichkeit, Stress, Sorgen und {\"A}ngste, schlechte Kindheit. Patienten mit Krankheitsursachen-Vorstellungen unterschieden sich weder durch allgemein soziodemographische noch durch krankheitsspezifische Daten. Sie waren jedoch signifikant depressiver. F{\"u}r die weitere Analyse erfolgte eine Aufteilung der Patienten nach der Art ihrer subjektiven Vorstellung in zwei polare Gruppen mit internal-psychischer versus external-k{\"o}rperlicher KUV. Dabei ließ sich zeigen, dass nicht das Vorhandensein von subjektiven Theorien als solches bereits mit h{\"o}herer Depressivit{\"a}t einhergeht. Vielmehr sind es allein die Patienten mit internal-psychischen Kausalattributionen, die zu h{\"o}heren Werten auf der Depressionsskala beitragen. Patienten mit eher external-k{\"o}rperlichen Erkl{\"a}rungsmodellen waren tendenziell sogar weniger depressiv als Patienten ohne KUV. Auch im L{\"a}ngsschnitt erfolgte zun{\"a}chst analog die Inhaltsanalyse, wobei im Wesentlichen {\"a}hnliche Inhaltskategorien gefunden wurden. Anschließend werden die Entwicklung, Dynamik und Konstanz von subjektiven Theorien anhand von Einzelverl{\"a}ufen untersucht: Zehn Patienten hatten nie Krankheitsursachen-Vorstellungen, sieben entwickelten sie erst im Untersuchungszeitraum, sechs hatten Vorstellungen von Anfang an, wobei drei davon einen inhaltlichen Wechsel vollzogen. Als Funktion dieser subjektiven Theorien konnte in zwei F{\"a}llen eine komplette Krankheitsverleugnung aufgezeigt werden, in vier F{\"a}llen erf{\"u}llten die Ursachenvorstellungen Kontrollfunktionen f{\"u}r die Erkrankung. Anschließend werden die Ergebnisse im Kontext des derzeitigen Forschungsstandes diskutiert sowie Probleme der Studie methodenkritisch analysiert. Die Bedeutung von internal-psychischen KUV als m{\"o}glicher Indikator f{\"u}r Patienten mit Problemen in der Krankheitsverarbeitung wird hervorgehoben. Hieraus werden Ans{\"a}tze f{\"u}r weiterf{\"u}hrende Forschungen sowie f{\"u}r die klinische Betreuung dieser Patienten abgeleitet.}, language = {de} } @phdthesis{Denkinger2006, author = {Denkinger, Claudia Maria}, title = {Untersuchungen zur Blockade des Makrophagen-Migrations-Inhibitionsfaktors in der Experimentellen Autoimmunen Enzephalomyelitis}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-17643}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2006}, abstract = {Der Makrophagen-Migrations-Inhibitionsfaktor (MIF) ist ein Chemokin, das eine wichtige Rolle bei der Regulation der Effektorfunktionen von Makrophagen und bei der T-Zell-Aktivierung und -Migration innehat. Untersuchungen zur Bedeutung des Chemokins in der Pathogenese von Autoimmunkrankheiten, wie der rheumatoiden Arthritis, wurden bereits durchgef{\"u}hrt und finden ihre Umsetzung in klinischen Studien zu einem m{\"o}glichen neuen Therapieansatz. Die vorliegende Arbeit hat zum Ziel, die Rolle von MIF in der Pathogenese der EAE aufzukl{\"a}ren und dadurch eventuell neue Aspekte der bislang nur unvollst{\"a}ndig verstandenen Krankheitsmechanismen aufzudecken. Außerdem soll eine Aussage dar{\"u}ber getroffen werden, ob anti-MIF-mAK als Therapie f{\"u}r die EAE und damit m{\"o}glicherweise auch f{\"u}r die MS in Frage kommt. Es konnte demonstriert werden, dass die Behandlung mit anti-MIF-mAK von PLPp139-151-induzierter EAE in SJL-M{\"a}usen in der akuten Phase der Erkrankung wirkt und zu einer schnelleren Besserung im Vergleich zu Kontroll-M{\"a}usen f{\"u}hrt. Des Weiteren wurde gezeigt, dass das „Homing" der pathogenen Neuroantigen-spezifischen T-Zellen in das ZNS durch die anti-MIF-mAK-Behandlung eingeschr{\"a}nkt ist. Als ein m{\"o}glicher Mechanismus konnte die verminderte Expression von VCAM-1 auf der Oberfl{\"a}che der Endothelzellen im Gehirn ausgemacht werden. Zus{\"a}tzlich reduzierte die MIF-Blockade die klonale Expansion und die Pathogenit{\"a}t der Neuroantigen-reaktiven CD4+-T-Zellen. Weitere Experimente f{\"u}hrten zu der Annahme, dass eine verminderte Zahl an funktionell hoch aviden T-Zellen, wahrscheinlich aufgrund erh{\"o}hter Apoptose, die eingeschr{\"a}nkte Pathogenit{\"a}t des T-Zell-Pools bedingt. Interessanterweise sind diese Ergebnisse unabh{\"a}ngig vom Mausstamm und vom Neuroantigen, mit dem immunisiert wurde. Zusammengefasst kann man daraus ableiten, dass die Blockade von MIF einen vielversprechenden neuen Ansatz in der Therapie der MS begr{\"u}nden k{\"o}nnte.}, language = {de} } @phdthesis{Schmid2007, author = {Schmid, Harriet}, title = {Die Wirkung des Phosphodiesterase-IV-Inhibitors Mesopram auf Faktoren der Blut-Hirn-Schranke}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-26345}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2007}, abstract = {Multiple Sklerose ist eine chronisch degenerative Erkrankung des ZNS, deren Therapie-m{\"o}glichkeiten noch immer begrenzt sind. In der vorliegenden Arbeit wurde in vitro der selektive PDE-IV-Inhibitor Mesopram untersucht, welcher bereits in einer Phase II Studie bei Patienten mit klinisch gesicherter MS zum Einsatz kommt. Anhand von HBMEC's, die als ein Model der menschlichen BHS gelten, konnten TJ's (ZO-1, Claudin-3, Occludin), Adh{\"a}sionsmolek{\"u}le (ICAM, VCAM, MCAM), Zytokine und Chemokine (AR, Il-6, MCP-1, Il-8) und MMP-2 nachgewiesen werden. Diese Faktoren sind bei der Zerst{\"o}rung der BHS in der Pathologie der MS beteiligt. Die Idee dieser Arbeit war es, durch die spezifische PDE-IV-Inhibition mit Mesopram die untersuchten Faktoren der BHS so zu beeinflussen, dass eine weitere Permeabilit{\"a}tserh{\"o}hung verhindert werden k{\"o}nnte. Da es sich bei MS um eine inflammatorische Erkrankung handelt und TNF\&\#945; in MS-L{\"a}sionen gefunden wird, wurde in dieser Arbeit TNF\&\#945; als inflammatorischer Stimulus verwendet. Unter TNF\&\#945;-Stimulation wurden die meisten der genannten Faktoren vermehrt exprimiert. Keine Ver{\"a}nderung unter TNF\&\#945; zeigten Occludin, ZO-1, VCAM und MMP-2. Die HBMEC's wurden {\"u}ber 24 und 48 h mit TNF\&\#945; und Mesopram stimuliert. Es konnte in den unterschiedlichen Auswertungen (ELISA, FACS, Western Blot, Zymographie) keine regulatorische Modulation der verschiedenen Faktoren unter Mesopram-induzierter cAMP-Erh{\"o}hung nachgewiesen werden.}, subject = {Blut-Hirn-Schranke}, language = {de} } @phdthesis{KronerMilsch2008, author = {Kroner-Milsch, Antje}, title = {Role of immune cells in hereditary myelinopathies}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-28976}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2008}, abstract = {Myelin mutations in the central and peripheral nervous system lead to severely disabling, currently untreatable diseases. In this study, we used transgenic PLP overexpressing mice (PLPtg) as a model for central inherited myelinopathies, such as leukodystrophies, and heterozygously P0 deficient (P0+/-) mice as models for peripheral hereditary polyneuropathies. Both models are characterized by low grade nervous tissue inflammation. Macrophages and CD8+ T- lymphocytes contribute to the myelin pathology as shown by crossbreeding experiments with immunodeficient mice. Having shown the relevance of CD8+ T- lymphocytes in PLPtg mice, we investigated the influence of one major cytotoxic molecule (granzyme B) on neural damage. By generation of granzyme B deficient PLPtg bone marrow chimeras, we could demonstrate a reduction of myelin pathology and oligodendrocyte death. Taken together, granzyme B is at least partly responsible for the cytotoxicity induced neural damage in PLPtg mice. To further explore the role of immune modulation, we focussed on the influence of the coinhibitory molecule PD-1, a CD28-related receptor expressed on activated T- and B-lymphocytes. By investigating myelin mutants of the CNS and PNS (PLPtg and P0+/-) with an additional PD-1 deficiency, induced by crossbreeding or bone marrow chimerization, we found a significant increase of CD8+ T- lymphocytes and massive increase of the myelin pathology in both the CNS and PNS model. In PLPtg mice, absence of PD-1 increased oligodendrocyte apoptosis, clonal expansions and a higher propensity of CNS but not peripheral CD8+ T- cells to secrete proinflammatory cytokines. In P0+/- mice, absence of PD-1 lead to moderate motor and sensory disturbances, confirming the important role of PD-1 in immune homeostasis. Taken together, we identified granzyme B as an important effector agent of cytotoxic T-lymphocytes in PLPtg mice and PD-1 as a crucial player in regulating the effector cells in our models of central and peripheral myelinopathy. Alterations of this regulatory pathway lead to overt neuroinflammation of high pathogenetic impact. These results might help to understand mechanisms responsible for high clinical variability of polygenic or even monogenic disorders of the nervous system.}, subject = {Myelinopathie}, language = {en} } @phdthesis{Blecharz2009, author = {Blecharz, Kinga Grażyna}, title = {Molekulare Ziele der Glukokortikoidbehandlung unter verschiedenen pathophysiologischen Bedingungen in einem in vitro Modell der Blut-Hirn-Schranke}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-57256}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2009}, abstract = {Die Integrit{\"a}t der Blut-Hirn-Schranke (BHS) ist bei vielen Erkrankungen des humanen zentralen Nervensystems (ZNS) beeintr{\"a}chtigt. Unter verschiedenen neuroinflammatorischen Bedingungen, wie bei zerebralen Isch{\"a}mien, Traumata, Hirntumoren oder der Multiplen Sklerose (MS), kommt es zum Verlust der protektiven Schrankenfunktion. Zu den ersten Anzeichen des BHS-Zusammenbruchs z{\"a}hlt der Verlust der Zell-Zell-Adh{\"a}sion: der Adh{\"a}rens- und Occludenskontakte. Therapeutische Maßnahmen dieser Krankheiten beinhalten Behandlungen mit Glukokortikoiden (GCs), wobei der Mechanismus und die Wirkungsweise dieser Substanzen bis heute nicht vollkommen aufgekl{\"a}rt sind. In der zerebralen Hirnendothelzelllinie cEND [Forster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J \& Drenckhahn D. (2005). Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol 565, 475-486] wurde eine Funktionsverbesserung der Endothelbarriere durch die Expressionerh{\"o}hung von Occludin nach GC-Behandlung bereits analysiert. Daraufhin wurden andere Kandidaten des apikalen Junktionssystems gesucht, die positiv auf GC-Gabe ansprechen. Der erste Teil der Arbeit pr{\"a}sentiert den positiven Einfluss der Dexamethason-Behandlung auf die Expression des Adh{\"a}renskontakt-Proteins VE- (Vascular-Endothelial) Cadherin in cEND-Zellen. Dabei wurde eine Reorganisation des Zytoskeletts, eine verst{\"a}rkte Verankerung des VE-Cadherins an das Zytoskelett, sowie eine einhergehende Morphologie{\"a}nderung der behandelten Zellen beobachtet. Untersuchungen der Transkriptionsaktivierung des VE-Cadherin-Promoters nach Dexamethason-Behandlung, wiesen auf einen indirekten Steroid-Effekt hin, der zu einer Erh{\"o}hung der VE-Cadherin-Proteinsynthese f{\"u}hrte. Somit sind GCs wichtig f{\"u}r die Proteinsynthese und -organisation beider Kontaktproteinarten: der Adh{\"a}rens- und Occludenskontakte in mikrovaskul{\"a}ren Hirnendothelzellen. Die Beeintr{\"a}chtigung der BHS-Integrit{\"a}t mit Ver{\"a}nderungen der Occludenskontaktexpression z{\"a}hlt zu den fr{\"u}hen Ereignissen bei der Entstehung einer Inflammation des ZNS, wie beispielsweise bei der MS. Im zweiten Teil der Dissertation wurde die Herunterregulation von Occludenskontaktproteinen in der cEND-Zelllinie untersucht. Dabei wurden cEND-Zellen mit Seren von Patienten, die sich in zwei verschiedenen Stadien der MS befanden, behandelt: in der akuten Exazerbationsphase oder der Remissionsphase, und auf die Protein- und Genexpression mit und ohne Dexamethasons-Behandlung untersucht. Es konnte ein negativer Effekt auf den Barrierewiderstand und die Occludenskontaktexpression, sowie eine erh{\"o}hte MMP-9-Genexpression nach Krankheitssereninkubation gezeigt werden. Die Dexamethason-Behandlung ergab eine geringe, aber keine vollst{\"a}ndige Rekonstitution der Barrierefunktion. Anhand dieser Studie konnte jedoch erstmals eine Erniedrigung der Protein- und mRNA-Synthese von Claudin-5 und Occludin in Remissionspatientenseren inkubierten cEND-Zellen demonstriert werden. Somit k{\"o}nnten diese Erkenntnisse zur Pr{\"a}diagnose einer bevorstehenden Exazerbationsphase der MS eingesetzt werden. Eine Langzeit-GC-Behandlung f{\"u}hrt zu zahlreichen Nebenwirkungen, u. a. zum Bluthochdruck, welcher aufgrund einer eingeschr{\"a}nkten Produktion des vasodilatativen Faktors Stickstoffmonoxid, NO, im myokardialen Endothel hervorgerufen wird. Ver{\"a}nderungen in der NO-Produktion, wie auch anderer Faktoren der NO-Signalkaskade in der myokardialen Endothelzelllinie MyEND unter Einfluss von Dexamethason standen im Zentrum des dritten Teils dieser Arbeit. W{\"a}hrend keine Ver{\"a}nderungen in der Expression der endothelialen NO-Synthase, eNOS, nach GC-Behandlung gezeigt werden konnten, wurden repressive Einfl{\"u}sse von Dexamethason auf die Enzymaktivit{\"a}t der eNOS in MyEND-Zellen untersucht. GC-Gabe f{\"u}hrte zur einer herabgesetzten Synthese des essenziellen Co-Faktors der eNOS, des Tetrahydrobiopterins, BH4, sowie zu einer Herunterregulation der GTP-Cyclohydrolase-1 (GTPCH-1), des geschwindigkeitsbestimmenden Enzyms der BH4-Produktion. Im Gegensatz zu bisherigen Ergebnissen anderer Arbeitsgruppen, konnte in der vorliegenden Studie belegt werden, dass die Herunterregulation der GTPCH-1 mRNA-Level auf den Liganden-abh{\"a}ngigen proteasomalen Abbau des Glukokortikoid-Rezeptors (GR) zur{\"u}ckzuf{\"u}hren ist. Das 26S-Proteasom moduliert die GR-abh{\"a}ngige Genexpression durch Kontrolle des Umsatzes und des Recyclings des Rezeptors selbst, wodurch eine regulierte Hormonresponsivit{\"a}t gew{\"a}hrleistet wird. Die Aufhebung des Liganden-abh{\"a}ngigen Abbaus des GR-Proteins durch gezielte Proteasominhibition, sowie durch eine {\"U}berexpression des ubiquitinylierungsdefekten GR-Konstruktes, K426A-GR, in Dexamethason-behandelten MyEND-Zellen resultierte in einer Erh{\"o}hung der GTPCH-1-Expression, sowie einer gesteigerten eNOS-Aktivit{\"a}t. Die hier beschriebenen Ergebnisse erlauben einen innovativen Einblick in die Erkenntnisse zur GC-vemittelten Hypertonie. Zusammenfassend kann festgestellt werden, dass GC-Behandlungen von mikrovaskul{\"a}ren Hirnendothelzellen zu einer Stabilisierung der Endothelbarriere f{\"u}hren. Unter pathologischen Bedingungen, wie der MS, wird der protektive GC-Effekt durch andere Faktoren beeintr{\"a}chtigt}, subject = {Blut-Hirn-Schranke}, language = {de} } @phdthesis{Ortler2009, author = {Ortler, Sonja}, title = {Die Bedeutung koinhibitorischer Signale in der ZNS Immunregulation: die Rolle des B7-Homologs B7-H1 (PD-L1)}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-34784}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2009}, abstract = {Das koinhibitorische Molek{\"u}l B7-H1 beeinflusst adaptive Immunantworten und ist vermutlich an den Mechanismen zur Aufrechterhaltung peripherer Toleranz und der Limitierung inflammatorischen Schadens beteiligt. Zus{\"a}tzlich kommt DZ eine entscheidende Bedeutung in der Entwicklung, Aufrechterhaltung und Regulation ZNS-spezifischer Autoimmunit{\"a}t und Inflammationsprozessen zu. Um den B7-H1/PD-1-Signalweg eingehender zu untersuchen, wurden adaptive Immunantworten und die Zielorgan-spezifische Infiltration im Modell der MOG35-55-induzierten EAE analysiert, einem Tiermodell der MS, das durch neurologische Sch{\"a}digungen und progressive Paralyse bedingt durch die inflammatorische Demyelinisierung im ZNS charakterisiert ist. Im Vergleich zu Wildtyptieren zeigten B7-H1-/- M{\"a}use einen beschleunigten Krankheitsbeginn und eine signifikante Steigerung des Schweregrads der EAE. Periphere MOG35-55-spezifische IFNg-/IL-17-Immunzellantworten traten in B7-H1-/- M{\"a}usen verfr{\"u}ht und verst{\"a}rkt auf, klangen allerdings auch schneller ab. Im ZNS persistierte jedoch eine signifikant h{\"o}here Anzahl aktivierter, Neuroantigen-spezifischer T-Zellen w{\"a}hrend allen Phasen der EAE, wobei diese Zellen ebenfalls gr{\"o}ßere Mengen proinflammatorischer Zytokine sezernieren konnten. Experimente mit APZ-assoziiertem B7-H1, die einen direkten inhibitorischen Effekt auf die Aktivierung und Proliferation MOG35-55-spezifischer Effektorzellen zeigten, unterst{\"u}tzen die Hypothese, dass parenchymale Expression von B7-H1 ausschlaggebend f{\"u}r das Schicksal von T-Zellen im Zielorgan ist. B7-H1 stellt damit ein Schl{\"u}sselmolek{\"u}l f{\"u}r die Kontrolle parenchymaler Immunreaktionen dar. Nachdem die Relevanz von B7-H1 auf APZ in vitro bewiesen werden konnte, wurde der Einfluss von B7-H1 auf systemisch oder intrazerebral injizierten DZ mit immunogenem oder tolerogenem Ph{\"a}notyp untersucht. Intraven{\"o}se Applikation von tolerogenen B7-H1-/- DZ resultierte in einer besseren Protektion gegen EAE, und dieser Effekt war von einer gesteigerten Produktion Tr1-/Th2-typischer Zytokine sowie einer verst{\"a}rkten Sekretion von IL-4 und IL-13 durch CD1d-restringierte T-Zellen in der Peripherie begleitet. Die Anzahl Neuroantigen-spezifischer T-Zellen, die proinflammatorische Zytokine sezernierten, war dementsprechend sowohl in der Peripherie als auch im ZNS reduziert. In diesem Zusammenhang konnte f{\"u}r B7-H1 eine wesentliche Beteiligung an der Inhibition der Aktivierung antigen-spezifischer, regulatorischer T-Zellen und CD1d-restringierter T-Zellen gefunden werden. Bei der Injektion intrazerebraler DZ bewirkten tolerogene DZ im Vergleich zu immunogenen DZ eine Reduktion der ZNS-Infiltration mit CD4+ T-Zellen in der fr{\"u}hen Phase der Erkrankung. Außerdem konnte eine Ver{\"a}nderung des intrazerebralen Zytokinmilieus von IFNg/IL-17 exprimierenden enzephalitogenen T-Zellen zu IL-10+ regulatorischen T-Zellen gezeigt werden. B7-H1-Defizienz auf APZ verst{\"a}rkte diesen Effekt und f{\"u}hrte dadurch in den M{\"a}usen zur partiellen Protektion gegen klinische Symptome der EAE. Zus{\"a}tzlich wurde die Beteiligung von B7-H1 an der Rekrutierung und ZNS-lokalisierten Induktion der Proliferation CD8+ regulatorischer T-Zellen durch DZ beschrieben. Unabh{\"a}ngig vom Ph{\"a}notyp der DZ wurde eine bereits in der fr{\"u}hen Phase vorhandene und dauerhaft expandierende Population von CD8+ T-Zellen im ZNS DZ[B7-H1-/-]-injizierter M{\"a}use gefunden. Diese Zellen konnten in vitro die Proliferation MOG35-55-spezifischer CD4+ T-Zellen supprimieren und wirkten so mutmaßlich an der Abmilderung der EAE mit. Zusammengefasst zeigen die Ergebnisse dieser Arbeit die entscheidende Bedeutung von B7 H1 auf DZ als immuninhibitorisches Molek{\"u}l, das sowohl enzephalitogene als auch regulatorische T-Zell-Antworten moduliert und damit zur Limitation von Immunantworten beitr{\"a}gt.}, subject = {Multiple Sklerose}, language = {de} } @phdthesis{Eujen2010, author = {Eujen, Heike Carola}, title = {Blockade der Antigenerkennung als therapeutische Strategie in einem CD8+ T-Zell vermittelten Mausmodell der Multiplen Sklerose}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-52052}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2010}, abstract = {Die Multiple Sklerose (MS) ist eine schwere, momentan noch unheilbare Autoimmunerkrankung des Zentralnervensystems, die weltweit ca. 1 Mio. Menschen betrifft. Da die zur Zeit verf{\"u}gbaren, anti-inflammatorischen und immunsuppressiven Therapieformen lediglich krankheitsverz{\"o}gernd wirken, ist es Gegenstand intensiver Forschungsbem{\"u}hungen, M{\"o}glichkeiten zur spezifischen Interferenz mit bei der MS ablaufenden Pathomechanismen zu ergr{\"u}nden und im Tiermodell zu testen. Das von uns f{\"u}r diese Arbeit verwendete Mausmodell einer CD8+ T-Zell vermittelten Experimentellen Autoimmunen Enzephalomyelitis (EAE) tr{\"a}gt dabei neuen Erkenntnissen Rechnung, die zeigen, dass zytotoxische T-Lymphozyten bei der Pathogenese der humanen MS von entscheidender Bedeutung sind. Es handelt sich um doppelt transgene Nachkommen von M{\"a}usen, die das Modell-Antigen Ovalbumin (OVA) unter der Kontrolle eines Oligodendrozyten (ODC-)-spezifischen MBP-Promotors im ZNS exprimieren, und M{\"a}usen, die Ovalbumin-spezifische CD8+ T-Zellen besitzen (OT-I Zellen). Es kommt in diesem Modell zur Autoantigenerkennung durch die CD8+ T-Zellen mit konsekutiver Ausbildung einer fulminanten, letal verlaufenden EAE. Ziel der vorliegenden Arbeit war es nun, die therapeutische Potenz des monoklonalen Antik{\"o}rpers 25-D1.16 zu evaluieren, der gegen das Autoantigen Ovalbumin in Kombination mit einem MHC-I-Molek{\"u}l gerichtet ist. Mit Hilfe von FACS-Analysen und Fluoreszenz-Mikroskopie konnten wir zun{\"a}chst best{\"a}tigen, dass 25-D1.16 spezifisch den Komplex aus dem Peptid SIINFEKL (antigenes Epitop von Ovalbumin) gebunden an ein MHC-I-Molek{\"u}l (H-2Kb) erkennt. In nachfolgenden in vitro Versuchen wurde der Einfluss des Antik{\"o}rpers auf Aktivierung und Proliferation von durch SIINFEKL:MHC-I-Komplex stimulierten OT-I Zellen untersucht. Es wurden hierf{\"u}r Zellproliferation (Proliferations-Assays), Expression des Oberfl{\"a}chenmolek{\"u}ls CD69 (FACS-Analysen) sowie IFN-γ-Sekretion (ELISA) gemessen. In Gegenwart von 25-D1.16 zeigte sich durchweg eine hochsignifikante Reduktion der jeweiligen Proliferations-/Aktivierungsmarker. Wir konnten somit in vitro zeigen, dass der gegen das Autoantigen Ovalbumin/H-2Kb gerichtete, monoklonale Antik{\"o}rper 25-D1.16 kompetitiv die Aktivierung und Proliferation entsprechender T-Lymphozyten inhibieren kann. Um diese Daten in vivo zu validieren und die pathogenetische Relevanz zu {\"u}berpr{\"u}fen, haben wir ODC-OVA/OT-I doppelt transgenen M{\"a}usen verschiedene Dosen von 25-D1.16 vor Auftreten erster EAE-Symptome einmalig intraperitoneal verabreicht. Anschließend wurde der Krankheitsverlauf klinisch beurteilt. Im EAE-Stadium 4 ohne Besserungstendenz oder bei Versuchsende wurden außerdem histologische Schnitte des Zentralnervensystems angefertigt, gef{\"a}rbt (H.E., CD3, Mac-3, Luxol Fast Blue/PAS) und mit unbehandelten Tieren verglichen. Ein Teil der ODC-OVA/OT-I doppelt transgenen Tiere blieb nach Applikation des Antik{\"o}rpers v{\"o}llig gesund, w{\"a}hrend bei einem anderen Teil der Ausbruch der EAE zwar nicht vollst{\"a}ndig verhindert, ihr Schweregrad aber deutlich gemildert wurde. Der Effekt der Antik{\"o}rpertherapie war jedoch nicht nur klinisch, sondern auch histopathologisch {\"u}berzeugend. So zeigte das Zentralnervensystem erfolgreich therapierter M{\"a}use eine weitgehend bis vollst{\"a}ndig intakte Gewebsarchitektur (H.E.-F{\"a}rbung) mit im Vergleich zu unbehandelten M{\"a}usen drastisch reduzierter OT-I Zell- und Makrophagen/Mikroglia-Infiltration (Immunhistochemie CD3 und Mac-3). In der Luxol Fast Blue/PAS-F{\"a}rbung fanden sich keinerlei Entmarkungsherde sondern durchg{\"a}ngig myelinisierte Axone. Es gelang uns somit durch hohe Antik{\"o}rperdosen (500 μg pro ODC-OVA/OT-I doppelt transgener Maus) bei 83 \% der behandelten Versuchstiere den Ausbruch der EAE ganz zu verhindern bzw. deren Verlauf deutlich abzumildern. Zusammenfassend beschreiben wir hier erstmals die antigen-spezifische Therapie einer CD8+ T-Zell mediierten EAE mittels eines gegen Peptid:MHC-I-Komplex gerichteten, monoklonalen Antik{\"o}rpers. Durch Interferenz mit der Erkennung des Autoantigens durch die CD8+ T-Zellen waren wir in vivo in der Lage, den Pathomechanismus der EAE zu inhibieren. Hieraus ergibt sich ein vielversprechendes Behandlungskonzept f{\"u}r die Therapie der Multiplen Sklerose am Menschen.}, subject = {Multiple Sklerose}, language = {de} } @phdthesis{Dang2011, author = {Dang, Su-Yin Judith}, title = {Funktionelle Bedeutung der Neuroplastizit{\"a}t bei Multipler Sklerose}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-73817}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2011}, abstract = {Die Multiple Sklerose ist eine chronische neurologische Erkrankung, welche in der industrialisierten Welt einen der h{\"a}ufigsten Gr{\"u}nde f{\"u}r eine bleibende Behinderung bei jungen Erwachsenen darstellt. Obwohl die ZNS-Sch{\"a}digung, charakterisiert durch Demyelinisierung und axonale Sch{\"a}digung im Rahmen entz{\"u}ndlicher Vorg{\"a}nge, durch verschiedene Reparaturmechanismen reduziert wird, akkumuliert die L{\"a}sionslast im zentralen Nervensystem mit der Zeit. T2-gewichtete MRT-Studien zeigen, dass die dargestellten Pathologien nur m{\"a}ßig mit den motorischen Defiziten korrelieren. Diese Diskrepanz wird unter anderem auf Vorg{\"a}nge der Neuroplastizit{\"a}t zur{\"u}ckgef{\"u}hrt, als deren Basismechanismen Langzeitpotenzierung (LTP) und -depression (LTD) gelten. In verschiedenen fMRT-Studien haben sich Hinweise ergeben, dass diese adaptiven Ver{\"a}nderungen zur Reorganisation kortikaler Repr{\"a}sentationmuster f{\"u}hren k{\"o}nnen, so dass bei MS-Patienten eine ausgedehntere Aktivierung ipsilateraler sensomotorischer Areale bei motorischen Aufgaben zu beobachten ist. Die transkranielle Magnetstimulation (TMS) bietet die M{\"o}glichkeit, mittels virtueller L{\"a}sionstechniken eine direkte Aussage {\"u}ber die kausale Beziehung zwischen Struktur und Funktion zu liefern. Die funktionelle Rolle ipsilateraler Motorareale wurde an 26 MS-Patienten, in Relation zu ihrer motorischen Beeintr{\"a}chtigung und ZNS-Sch{\"a}digung, und an nach Alter, Geschlecht und H{\"a}ndigkeit zugeordneten Kontrollprobanden, untersucht. Die motorische Leistungsf{\"a}higkeit wurde durch verschiedene Tests zur Handfunktion erhoben. Die ZNS-Sch{\"a}digung wurde mittels MR-Spektroskopie als NAA/Cr Quotient sowie durch die CML erhoben. Die Aufgabe zur einfachen Reaktionszeit (SRT) bestand aus einer isometrischen Abduktionsbewegung des rechten Daumens gegen einen Kraftaufnehmer auf ein akustisches Go-Signal. Mit TMS-Einzelreizen wurde mit Hilfe einer Neuronavigation eine reversible virtuelle L{\"a}sion {\"u}ber bestimmten Gehirnarealen, kontralateraler M1, ipsilateraler M1 und ipsilateraler PMd, erzeugt. Es wurde eine Kontrollstimulation {\"u}ber MO durchgef{\"u}hrt. Die TMS-Einzelreize wurden 100ms nach dem Go-Signal appliziert. Als SRT wurde der Zeitraum zwischen dem Go-Signal und EMG-Beginn im APB definiert. Die signifikanten SRT-Verl{\"a}ngerungen bei TMS {\"u}ber dem ipsilateralen M1 und dem ipsilateralen PMd zeigen, dass diese Regionen eine Rolle bei der motorischen Funktion bei MS spielen. Die fehlenden Korrelationen zwischen motorischen Funktionstest und NAA/Cr-Verh{\"a}ltnis sowie die inverse Korrelation zur kortikomuskul{\"a}ren Latenz sind durch strukturell von der krankheitsbedingten Pathologie betroffenen kompensierenden Gehirnregionen erkl{\"a}rbar. Bei dem Theta Burst Experiments (TBS) wurde ein virtueller L{\"a}sionseffekt durch eine repetitive TMS-Intervention {\"u}ber dem ipsilateralen M1 induziert. Die Ergebnisse zeigen {\"a}hnliche Ver{\"a}nderungen der Exzitabilit{\"a}t bei MS-Patienten und gesunden Kontrollprobanden, was schließen l{\"a}sst, dass die LTD bei mild bis moderat betroffenen MS-Patienten weitestgehend unbeeintr{\"a}chtigt ist. MS-Patienten zeigen im Vergleich zu den Kontrollen eine {\"a}hnliche Minderung der Verhaltensleistung, Trefferquote in ein Kraftfenster, der MS-Patienten im Kontrollvergleich. Die Ergebnisse zeigen, dass ipsilaterale motorische Areale in der Lage sind den prim{\"a}r motorischen Kortex soweit zu kompensieren, jedoch die F{\"a}higkeit zur Kompensation in fortgeschrittenen Krankheitsstadien eingeschr{\"a}nkt ist. Abschließend kann man zusammenfassen, dass die funktionelle Rekrutierung von ipsilateralen Motorarealen eine adaptive Antwort auf chronische Gehirnsch{\"a}digung bei MS-Patienten sein kann, allerdings mit Einschr{\"a}nkung der Kapazit{\"a}t in fortgeschrittenen Krankheitsstadien. Nachdem die synaptische Plastizit{\"a}t weitestgehend intakt scheint, sollte man besonders Mechanismen der sp{\"a}ten Phase der Plastizit{\"a}t f{\"o}rdern, welche auf eine langfristige kortikale Plastizit{\"a}t abzielen. Weitere Studien in diesem Forschungszweig k{\"o}nnten einen Beitrag zur Entwicklung therapeutischer Konzepte der Neurorehabilitation bei Multipler Sklerose leisten.}, subject = {Neuronale Plastizit{\"a}t}, language = {de} } @phdthesis{Fackelmann2011, author = {Fackelmann, Stefanie}, title = {Langzeitkorrelation evozierter Potentialparameter mit dem klinischen Verlauf bei Patienten mit Multipler Sklerose}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-64840}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2011}, abstract = {Evozierte Potenziale werden bereits als Hilfsmittel zur Diagnosestellung der Multiplen Sklerose herangezogen. Das Spektrum der Verl{\"a}ufe der Erkrankung ist sehr unterschiedlich. Ziel der Studie war es, zu pr{\"u}fen, ob visuell (VEP), somatosensibel (SEP) und Magnet- (MEP) evozierte Potentiale durch das Aufdecken klinisch noch stummer L{\"a}sionen eine prognostische Bedeutung haben. Es wurden 94 Patienten bei Erstvorstellung sowie zum 5-Jahres- und 10-Jahresverlaufszeitpunkt untersucht. Es wurde ein Zusammenhang von MEP- und SEP-Scores mit dem sp{\"a}teren Behinderungsgrad, gemessen in Form der EDSS nach f{\"u}nf und zehn jahren gefunden, sofern die elektrophysiologischen Untersuchungen in den ersten beiden Jahren nach Erstmanifestation klinischer Symptome durchgef{\"u}hrt worden waren (Gruppe 1, 44 Patienten). F{\"u}r Gruppe 2 (50 Patienten), deren Erstuntersuchung sp{\"a}ter im Verlauf stattgefunden hatte (im Mittel 9,6a) konnte keine prognostische Bedeutung gesehen werden. Die Durchf{\"u}hrung multimodaler evozierter Potenziale ist kann somit eine Hilfestellung zur fr{\"u}hzeitigen Therapieentscheidung geben.}, subject = {Multiple Sklerose}, language = {de} } @article{JariusRuprechtWildemannetal.2012, author = {Jarius, Sven and Ruprecht, Klemens and Wildemann, Brigitte and Kuempfel, Tania and Ringelstein, Marius and Geis, Christian and Kleiter, Ingo and Kleinschnitz, Christoph and Berthele, Achim and Brettschneider, Johannes and Hellwig, Kerstin and Hemmer, Bernhard and Linker, Ralf A. and Lauda, Florian and Hayrettin, Christoph A. and Tumani, Hayrettin and Melms, Arthur and Trebst, Corinna and Stangel, Martin and Marziniak, Martin and Hoffmann, Frank and Schippling, Sven and Faiss, J{\"u}rgen H. and Neuhaus, Oliver and Ettrich, Barbara and Zentner, Christian and Guthke, Kersten and Hofstadt-van Oy, Ulrich and Reuss, Reinhard and Pellkofer, Hannah and Ziemann, Ulf and Kern, Peter and Wandinger, Klaus P. and Bergh, Florian Then and Boettcher, Tobias and Langel, Stefan and Liebetrau, Martin and Rommer, Paulus S. and Niehaus, Sabine and M{\"u}nch, Christoph and Winkelmann, Alexander and Zettl, Uwe K and Metz, Imke and Veauthier, Christian and Sieb, J{\"o}rn P. and Wilke, Christian and Hartung, Hans P. and Aktas, Orhan and Paul, Friedemann}, title = {Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients}, series = {Journal of Neuroinflammation}, volume = {9}, journal = {Journal of Neuroinflammation}, number = {14}, doi = {10.1186/1742-2094-9-14}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-133636}, year = {2012}, abstract = {Background: The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity. Objective: To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus. Methods: Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3\%). Results: Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of <= 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades <= 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions >= 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.}, language = {en} } @article{KirylukYifuSannaCherchietal.2012, author = {Kiryluk, Krzysztof and Yifu, Li and Sanna-Cherchi, Simone and Rohanizadegan, Mersedeh and Suzuki, Hitoshi and Eitner, Frank and Snyder, Holly J. and Choi, Murim and Hou, Ping and Scolari, Francesco and Izzi, Claudia and Gigante, Maddalena and Gesualdo, Loreto and Savoldi, Silvana and Amoroso, Antonio and Cusi, Daniele and Zamboli, Pasquale and Julian, Bruce A. and Novak, Jan and Wyatt, Robert J. and Mucha, Krzysztof and Perola, Markus and Kristiansson, Kati and Viktorin, Alexander and Magnusson, Patrik K. and Thorleifsson, Gudmar and Thorsteinsdottir, Unnur and Stefansson, Kari and Boland, Anne and Metzger, Marie and Thibaudin, Lise and Wanner, Christoph and Jager, Kitty J. and Goto, Shin and Maixnerova, Dita and Karnib, Hussein H. and Nagy, Judit and Panzer, Ulf and Xie, Jingyuan and Chen, Nan and Tesar, Vladimir and Narita, Ichiei and Berthoux, Francois and Floege, J{\"u}rgen and Stengel, Benedicte and Zhang, Hong and Lifton, Richard P. and Gharavi, Ali G.}, title = {Geographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis}, series = {PLoS Genetics}, volume = {8}, journal = {PLoS Genetics}, number = {6}, doi = {10.1371/journal.pgen.1002765}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130195}, pages = {e1002765}, year = {2012}, abstract = {IgA nephropathy (IgAN), major cause of kidney failure worldwide, is common in Asians, moderately prevalent in Europeans, and rare in Africans. It is not known if these differences represent variation in genes, environment, or ascertainment. In a recent GWAS, we localized five IgAN susceptibility loci on Chr.6p21 (HLA-DQB1/DRB1, PSMB9/TAP1, and DPA1/DPB2 loci), Chr.1q32 (CFHR3/R1 locus), and Chr.22q12 (HORMAD2 locus). These IgAN loci are associated with risk of other immune-mediated disorders such as type I diabetes, multiple sclerosis, or inflammatory bowel disease. We tested association of these loci in eight new independent cohorts of Asian, European, and African-American ancestry (N = 4,789), followed by meta-analysis with risk-score modeling in 12 cohorts (N = 10,755) and geospatial analysis in 85 world populations. Four susceptibility loci robustly replicated and all five loci were genome-wide significant in the combined cohort (P = 5x10\(^{-32}\) 3x10\(^{-10}\), with heterogeneity detected only at the PSMB9/TAP1 locus (I\(^{-2}\) = 0.60). Conditional analyses identified two new independent risk alleles within the HLA-DQB1/DRB1 locus, defining multiple risk and protective haplotypes within this interval. We also detected a significant genetic interaction, whereby the odds ratio for the HORMAD2 protective allele was reversed in homozygotes for a CFHR3/R1 deletion (P = 2.5x10\(^{-4}\)). A seven-SNP genetic risk score, which explained 4.7\% of overall IgAN risk, increased sharply with Eastward and Northward distance from Africa (r = 0.30, P = 3x10\(^{-128}\)). This model paralleled the known East-West gradient in disease risk. Moreover, the prediction of a South-North axis was confirmed by registry data showing that the prevalence of IgAN-attributable kidney failure is increased in Northern Europe, similar to multiple sclerosis and type I diabetes. Variation at IgAN susceptibility loci correlates with differences in disease prevalence among world populations. These findings inform genetic, biological, and epidemiological investigations of IgAN and permit cross-comparison with other complex traits that share genetic risk loci and geographic patterns with IgAN.}, language = {en} } @article{IpKronerGrohetal.2012, author = {Ip, Chi Wang and Kroner, Antje and Groh, Janos and Huber, Marianne and Klein, Dennis and Spahn, Irene and Diem, Ricarda and Williams, Sarah K. and Nave, Klaus-Armin and Edgar, Julia M. and Martini, Rudolf}, title = {Neuroinflammation by Cytotoxic T-Lymphocytes Impairs Retrograde Axonal Transport in an Oligodendrocyte Mutant Mouse}, series = {PLoS One}, volume = {7}, journal = {PLoS One}, number = {8}, doi = {10.1371/journal.pone.0042554}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134982}, pages = {e42554}, year = {2012}, abstract = {Mice overexpressing proteolipid protein (PLP) develop a leukodystrophy-like disease involving cytotoxic, CD8+ T-lymphocytes. Here we show that these cytotoxic T-lymphocytes perturb retrograde axonal transport. Using fluorogold stereotactically injected into the colliculus superior, we found that PLP overexpression in oligodendrocytes led to significantly reduced retrograde axonal transport in retina ganglion cell axons. We also observed an accumulation of mitochondria in the juxtaparanodal axonal swellings, indicative for a disturbed axonal transport. PLP overexpression in the absence of T-lymphocytes rescued retrograde axonal transport defects and abolished axonal swellings. Bone marrow transfer from wildtype mice, but not from perforin- or granzyme B-deficient mutants, into lymphocyte-deficient PLP mutant mice led again to impaired axonal transport and the formation of axonal swellings, which are predominantly located at the juxtaparanodal region. This demonstrates that the adaptive immune system, including cytotoxic T-lymphocytes which release perforin and granzyme B, are necessary to perturb axonal integrity in the PLP-transgenic disease model. Based on our observations, so far not attended molecular and cellular players belonging to the immune system should be considered to understand pathogenesis in inherited myelin disorders with progressive axonal damage.}, language = {en} } @article{ArndtHoffackerZellmeretal.2014, author = {Arndt, Andreas and Hoffacker, Peter and Zellmer, Konstantin and Goecer, Oktay and Recks, Mascha S. and Kuerten, Stefanie}, title = {Conventional Housing Conditions Attenuate the Development of Experimental Autoimmune Encephalomyelitis}, series = {PLoS ONE}, volume = {9}, journal = {PLoS ONE}, number = {6}, doi = {10.1371/journal.pone.0099794}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119603}, pages = {e99794}, year = {2014}, abstract = {BACKGROUND: The etiology of multiple sclerosis (MS) has remained unclear, but a causative contribution of factors outside the central nervous system (CNS) is conceivable. It was recently suggested that gut bacteria trigger the activation of CNS-reactive T cells and the development of demyelinative disease. METHODS: C57BL/6 (B6) mice were kept either under specific pathogen free or conventional housing conditions, immunized with the myelin basic protein (MBP)-proteolipid protein (PLP) fusion protein MP4 and the development of EAE was clinically monitored. The germinal center size of the Peyer's patches was determined by immunohistochemistry in addition to the level of total IgG secretion which was assessed by ELISPOT. ELISPOT assays were also used to measure MP4-specific T cell and B cell responses in the Peyer's patches and the spleen. Ear swelling assays were performed to determine the extent of delayed-type hypersensitivity reactions in specific pathogen free and conventionally housed mice. RESULTS: In B6 mice that were actively immunized with MP4 and kept under conventional housing conditions clinical disease was significantly attenuated compared to specific pathogen free mice. Conventionally housed mice displayed increased levels of IgG secretion in the Peyer's patches, while the germinal center formation in the gut and the MP4-specific TH17 response in the spleen were diminished after immunization. Accordingly, these mice displayed an attenuated delayed type hypersensitivity (DTH) reaction in ear swelling assays. CONCLUSIONS: The data corroborate the notion that housing conditions play a substantial role in the induction of murine EAE and suggest that the presence of gut bacteria might be associated with a decreased immune response to antigens of lower affinity. This concept could be of importance for MS and calls for caution when considering the therapeutic approach to treat patients with antibiotics."}, language = {en} } @article{KellerLeidingerVogeletal.2014, author = {Keller, Andreas and Leidinger, Petra and Vogel, Britta and Backes, Christina and ElSharawy, Abdou and Galata, Valentina and Mueller, Sabine C. and Marquart, Sabine and Schrauder, Michael G. and Strick, Reiner and Bauer, Andrea and Wischhusen, J{\"o}rg and Beier, Markus and Kohlhaas, Jochen and Katus, Hugo A. and Hoheisel, J{\"o}rg and Franke, Andre and Meder, Benjamin and Meese, Eckart}, title = {miRNAs can be generally associated with human pathologies as exemplified for miR-144*}, series = {BMC MEDICINE}, volume = {12}, journal = {BMC MEDICINE}, issn = {1741-7015}, doi = {10.1186/s12916-014-0224-0}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-114349}, pages = {224}, year = {2014}, abstract = {Background: miRNA profiles are promising biomarker candidates for a manifold of human pathologies, opening new avenues for diagnosis and prognosis. Beyond studies that describe miRNAs frequently as markers for specific traits, we asked whether a general pattern for miRNAs across many diseases exists. Methods: We evaluated genome-wide circulating profiles of 1,049 patients suffering from 19 different cancer and non-cancer diseases as well as unaffected controls. The results were validated on 319 individuals using qRT-PCR. Results: We discovered 34 miRNAs with strong disease association. Among those, we found substantially decreased levels of hsa-miR-144* and hsa-miR-20b with AUC of 0.751 ( 95\% CI: 0.703-0.799), respectively. We also discovered a set of miRNAs, including hsa-miR-155*, as rather stable markers, offering reasonable control miRNAs for future studies. The strong downregulation of hsa-miR-144* and the less variable pattern of hsa-miR-155* has been validated in a cohort of 319 samples in three different centers. Here, breast cancer as an additional disease phenotype not included in the screening phase has been included as the 20th trait. Conclusions: Our study on 1,368 patients including 1,049 genome-wide miRNA profiles and 319 qRT-PCR validations further underscores the high potential of specific blood-borne miRNA patterns as molecular biomarkers. Importantly, we highlight 34 miRNAs that are generally dysregulated in human pathologies. Although these markers are not specific to certain diseases they may add to the diagnosis in combination with other markers, building a specific signature. Besides these dysregulated miRNAs, we propose a set of constant miRNAs that may be used as control markers.}, language = {en} } @article{HaarmannNehenDeissetal.2015, author = {Haarmann, Axel and Nehen, Mathias and Deiß, Annika and Buttmann, Mathias}, title = {Fumaric acid esters do not reduce inflammatory NF-\(\kappa\)B/p65 nuclear translocation, ICAM-1 expression and T-cell adhesiveness of human brain microvascular endothelial cells}, series = {International Journal of Molecular Sciences}, volume = {16}, journal = {International Journal of Molecular Sciences}, doi = {10.3390/ijms160819086}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148295}, pages = {19086-19095}, year = {2015}, abstract = {Dimethyl fumarate (DMF) is approved for disease-modifying treatment of patients with relapsing-remitting multiple sclerosis. Animal experiments suggested that part of its therapeutic effect is due to a reduction of T-cell infiltration of the central nervous system (CNS) by uncertain mechanisms. Here we evaluated whether DMF and its primary metabolite monomethyl fumarate (MMF) modulate pro-inflammatory intracellular signaling and T-cell adhesiveness of nonimmortalized single donor human brain microvascular endothelial cells at low passages. Neither DMF nor MMF at concentrations of 10 or 50 \(\mu\)M blocked the IL-1\(\beta\)-induced nuclear translocation of NF-\(\kappa\)B/p65, whereas the higher concentration of DMF inhibited the nuclear entry of p65 in human umbilical vein endothelium cultured in parallel. DMF and MMF also did not alter the IL-1\(\beta\)-stimulated activation of p38 MAPK in brain endothelium. Furthermore, neither DMF nor MMF reduced the basal or IL-1\(\beta\)-inducible expression of ICAM-1. In accordance, both fumaric acid esters did not reduce the adhesion of activated Jurkat T cells to brain endothelium under basal or inflammatory conditions. Therefore, brain endothelial cells probably do not directly mediate a potential blocking effect of fumaric acid esters on the inflammatory infiltration of the CNS by T cells.}, language = {en} } @article{SchreweLillLiuetal.2015, author = {Schrewe, L. and Lill, C. M. and Liu, T. and Salmen, A. and Gerdes, L. A. and Guillot-Noel, L. and Akkad, D. A. and Blaschke, P. and Graetz, C. and Hoffjan, S. and Kroner, A. and Demir, S. and B{\"o}hme, A. and Rieckmann, P. and El Ali, A. and Hagemann, N. and Hermann, D. M. and Cournu-Rebeix, I. and Zipp, F. and K{\"u}mpfel, T. and Buttmann, M. and Zettl, U. K. and Fontaine, B. and Bertram, L. and Gold, R. and Chan, A.}, title = {Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS}, series = {Journal of Neuroinflammation}, volume = {12}, journal = {Journal of Neuroinflammation}, number = {234}, doi = {10.1186/s12974-015-0429-y}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-136252}, year = {2015}, abstract = {Background: Despite pleiotropic immunomodulatory effects of apolipoprotein E (apoE) in vitro, its effects on the clinical course of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) are still controversial. As sex hormones modify immunomodulatory apoE functions, they may explain contentious findings. This study aimed to investigate sex-specific effects of apoE on disease course of EAE and MS. Methods: MOG\(_{35-55}\) induced EAE in female and male apoE-deficient mice was assessed clinically and histopathologically. apoE expression was investigated by qPCR. The association of the MS severity score (MSSS) and APOE rs429358 and rs7412 was assessed across 3237 MS patients using linear regression analyses. Results: EAE disease course was slightly attenuated in male apoE-deficient (apoE\(^{-/-}\)) mice compared to wildtype mice (cumulative median score: apoE\(^{-/-}\) = 2 [IQR 0.0-4.5]; wildtype = 4 [IQR 1.0-5.0]; n = 10 each group, p = 0.0002). In contrast, EAE was more severe in female apoE\(^{-/-}\) mice compared to wildtype mice (cumulative median score: apoE\(^{-/-}\) = 3 [IQR 2.0-4.5]; wildtype = 3 [IQR 0.0-4.0]; n = 10, p = 0.003). In wildtype animals, apoE expression during the chronic EAE phase was increased in both females and males (in comparison to naive animals; p < 0.001). However, in MS, we did not observe a significant association between MSSS and rs429358 or rs7412, neither in the overall analyses nor upon stratification for sex. Conclusions: apoE exerts moderate sex-specific effects on EAE severity. However, the results in the apoE knock-out model are not comparable to effects of polymorphic variants in the human APOE gene, thus pinpointing the challenge of translating findings from the EAE model to the human disease.}, language = {en} } @article{RuckBittnerAfzalietal.2015, author = {Ruck, Tobias and Bittner, Stefan and Afzali, Ali Maisam and G{\"o}bel, Kerstin and Glumm, Sarah and Kraft, Peter and Sommer, Claudia and Kleinschnitz, Christoph and Preusse, Corinna and Stenzel, Werner and Wiendl, Heinz and Meuth, Sven G.}, title = {The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies}, series = {Oncotarget}, volume = {6}, journal = {Oncotarget}, number = {41}, doi = {10.18632/oncotarget.6462}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-136047}, year = {2015}, abstract = {NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.}, language = {en} } @article{RovitusoDuffySchroeteretal.2015, author = {Rovituso, Damiano M. and Duffy, Catharina E. and Schroeter, Michael and Kaiser, Claudia C. and Kleinschnitz, Christoph and Bayas, Antonios and Elsner, Rebecca and Kuerten, Stefanie}, title = {The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients}, series = {Scientific Reports}, volume = {5}, journal = {Scientific Reports}, number = {14265}, doi = {10.1038/srep14265}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148172}, year = {2015}, abstract = {B cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patients without this reactivity. Only in patients that classified as B cell responders, there was a significant positive correlation between treatment duration and the time since last relapse in our study. This correlation was GA-specific because it was absent in a control group that consisted of interferon-\(\beta\) (IFN-\(\beta\))-treated RRMS patients (n = 23). These data suggest that GA has an effect on brain-reactive B cells in a subset of patients and that only this subset benefits from treatment. The detection of brain-reactive B cells is likely to be a suitable tool to identify drug responders.}, language = {en} } @article{RottlaenderKuerten2015, author = {Rottlaender, Andrea and Kuerten, Stefanie}, title = {Stepchild or prodigy? Neuroprotection in multiple sclerosis (MS) research}, series = {International Journal of Molecular Sciences}, volume = {16}, journal = {International Journal of Molecular Sciences}, doi = {10.3390/ijms160714850}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148416}, pages = {14850-14865}, year = {2015}, abstract = {Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) and characterized by the infiltration of immune cells, demyelination and axonal loss. Loss of axons and nerve fiber pathology are widely accepted as correlates of neurological disability. Hence, it is surprising that the development of neuroprotective therapies has been neglected for a long time. A reason for this could be the diversity of the underlying mechanisms, complex changes in nerve fiber pathology and the absence of biomarkers and tools to quantify neuroregenerative processes. Present therapeutic strategies are aimed at modulating or suppressing the immune response, but do not primarily attenuate axonal pathology. Yet, target-oriented neuroprotective strategies are essential for the treatment of MS, especially as severe damage of nerve fibers mostly occurs in the course of disease progression and cannot be impeded by immune modulatory drugs. This review shall depict the need for neuroprotective strategies and elucidate difficulties and opportunities.}, language = {en} } @article{KolbMaeurerGoebelerMaeurer2015, author = {Kolb-M{\"a}urer, Annette and Goebeler, Matthias and M{\"a}urer, Mathias}, title = {Cutaneous adverse events associated with interferon-\(\beta\) treatment of multiple sclerosis}, series = {International Journal of Molecular Sciences}, volume = {16}, journal = {International Journal of Molecular Sciences}, doi = {10.3390/ijms160714951}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148451}, pages = {14951-14960}, year = {2015}, abstract = {Interferons are widely used platform therapies as disease-modifying treatment of patients with multiple sclerosis. Although interferons are usually safe and well tolerated, they frequently cause dermatological side effects. Here, we present a multiple sclerosis (MS) patient treated with interferon-\(\beta\) who developed new-onset psoriasis. Both her MS as well as her psoriasis finally responded to treatment with fumarates. This case illustrates that interferons not only cause local but also systemic adverse events of the skin. These systemic side effects might indicate that the Th17/IL-17 axis plays a prominent role in the immunopathogenesis of this individual case and that the autoimmune process might be deteriorated by further administration of interferons. In conclusion, we think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. We suggest that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.}, language = {en} } @article{BittnerBobakHofmannetal.2015, author = {Bittner, Stefan and Bobak, Nicole and Hofmann, Majella-Sophie and Schuhmann, Michael K. and Ruck, Tobias and G{\"o}bel, Kerstin and Br{\"u}ck, Wolfgang and Wiendl, Heinz and Meuth, Sven G.}, title = {Murine K\(_{2P}\)5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K\(_{2P}\)3.1-and K\(_{V}\)1.3-Dependent Mechanisms}, series = {International Journal of Molecular Sciences}, volume = {16}, journal = {International Journal of Molecular Sciences}, doi = {10.3390/ijms160816880}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-151454}, pages = {16880 -- 16896}, year = {2015}, abstract = {Lymphocytes express potassium channels that regulate physiological cell functions, such as activation, proliferation and migration. Expression levels of K\(_{2P}\)5.1(TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis. In humans, K\(_{2P}\)5.1 channels are upregulated upon T cell stimulation and influence T cell effector functions. However, a further clinical translation of targeting K\(_{2P}\)5.1 is currently hampered by a lack of highly selective inhibitors, making it necessary to evaluate the impact of KCNK5 in established preclinical animal disease models. We here demonstrate that K\(_{2P}\)5.1 knockout (K\(_{2P}\)5.1\(^{-/-}\) mice display no significant alterations concerning T cell cytokine production, proliferation rates, surface marker molecules or signaling pathways. In an experimental model of autoimmune neuroinflammation, K\(_{2P}\)5.1\(^{-/-}\) mice show a comparable disease course to wild-type animals and no major changes in the peripheral immune system or CNS compartment. A compensatory upregulation of the potassium channels K\(_{2P}\)3.1 and K\(_{V}\)1.3 seems to counterbalance the deletion of K\(_{2P}\)5.1. As an alternative model mimicking autoimmune neuroinflammation, experimental autoimmune encephalomyelitis in the common marmoset has been proposed, especially for testing the efficacy of new potential drugs. Initial experiments show that K\(_{2P}\)5.1 is functionally expressed on marmoset T lymphocytes, opening up the possibility for assessing future K\(_{2P}\)5.1-targeting drugs.}, language = {en} } @article{RovitusoSchefflerWunschetal.2016, author = {Rovituso, Damiano M. and Scheffler, Laura and Wunsch, Marie and Kleinschnitz, Christoph and D{\"o}rck, Sebastian and Ulzheimer, Jochen and Bayas, Antonios and Steinman, Lawrence and Erg{\"u}n, S{\"u}leyman and Kuerten, Stefanie}, title = {CEACAM1 mediates B cell aggregation in central nervous system autoimmunity}, series = {Scientific Reports}, volume = {6}, journal = {Scientific Reports}, doi = {10.1038/srep29847}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-147690}, pages = {29847}, year = {2016}, abstract = {B cell aggregates in the central nervous system (CNS) have been associated with rapid disease progression in patients with multiple sclerosis (MS). Here we demonstrate a key role of carcinoembryogenic antigen-related cell adhesion molecule1 (CEACAM1) in B cell aggregate formation in MS patients and a B cell-dependent mouse model of MS. CEACAM1 expression was increased on peripheral blood B cells and CEACAM1\(^+\) B cells were present in brain infiltrates of MS patients. Administration of the anti-CEACAM1 antibody T84.1 was efficient in blocking aggregation of B cells derived from MS patients. Along these lines, application of the monoclonal anti-CEACAM1 antibody mCC1 was able to inhibit CNS B cell aggregate formation and significantly attenuated established MS-like disease in mice in the absence of any adverse effects. CEACAM1 was co-expressed with the regulator molecule T cell immunoglobulin and mucin domain -3 (TIM-3) on B cells, a novel molecule that has recently been described to induce anergy in T cells. Interestingly, elevated coexpression on B cells coincided with an autoreactive T helper cell phenotype in MS patients. Overall, these data identify CEACAM1 as a clinically highly interesting target in MS pathogenesis and open new therapeutic avenues for the treatment of the disease.}, language = {en} } @article{SadovnickTraboulseeBernalesetal.2016, author = {Sadovnick, A. Dessa and Traboulsee, Anthony L. and Bernales, Cecily Q. and Ross, Jay P. and Forwell, Amanda L. and Yee, Irene M. and Guillot-Noel, Lena and Fontaine, Bertrand and Cournu-Rebeix, Isabelle and Alcina, Antonio and Fedetz, Maria and Izquierdo, Guillermo and Matesanz, Fuencisla and Hilven, Kelly and Dubois, B{\´e}n{\´e}dicte and Goris, An and Astobiza, Ianire and Alloza, Iraide and Antig{\"u}edad, Alfredo and Vandenbroeck, Koen and Akkad, Denis A. and Aktas, Orhan and Blaschke, Paul and Buttmann, Mathias and Chan, Andrew and Epplen, Joerg T. and Gerdes, Lisa-Ann and Kroner, Antje and Kubisch, Christian and K{\"u}mpfel, Tania and Lohse, Peter and Rieckmann, Peter and Zettl, Uwe K. and Zipp, Frauke and Bertram, Lars and Lill, Christina M. and Fernandez, Oscar and Urbaneja, Patricia and Leyva, Laura and Alvarez-Cerme{\~n}o, Jose Carlos and Arroyo, Rafael and Garagorri, Aroa M. and Garc{\´i}a-Mart{\´i}nez, Angel and Villar, Luisa M. and Urcelay, Elena and Malhotra, Sunny and Montalban, Xavier and Comabella, Manuel and Berger, Thomas and Fazekas, Franz and Reindl, Markus and Schmied, Mascha C. and Zimprich, Alexander and Vilari{\~n}o-G{\"u}ell, Carles}, title = {Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients}, series = {G3: Genes Genomes Genetics}, volume = {6}, journal = {G3: Genes Genomes Genetics}, number = {7}, doi = {10.1534/g3.116.030841}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-165405}, pages = {2073-2079}, year = {2016}, abstract = {Multiple sclerosis (MS) is a prevalent neurological disease of complex etiology. Here, we describe the characterization of a multi-incident MS family that nominated a rare missense variant (p.G420D) in plasminogen (PLG) as a putative genetic risk factor for MS. Genotyping of PLG p.G420D (rs139071351) in 2160 MS patients, and 886 controls from Canada, identified 10 additional probands, two sporadic patients and one control with the variant. Segregation in families harboring the rs139071351 variant, identified p.G420D in 26 out of 30 family members diagnosed with MS, 14 unaffected parents, and 12 out of 30 family members not diagnosed with disease. Despite considerably reduced penetrance, linkage analysis supports cosegregation of PLG p.G420D and disease. Genotyping of PLG p.G420D in 14446 patients, and 8797 controls from Canada, France, Spain, Germany, Belgium, and Austria failed to identify significant association with disease (P = 0.117), despite an overall higher prevalence in patients (OR = 1.32; 95\% CI = 0.93-1.87). To assess whether additional rare variants have an effect on MS risk, we sequenced PLG in 293 probands, and genotyped all rare variants in cases and controls. This analysis identified nine rare missense variants, and although three of them were exclusively observed in MS patients, segregation does not support pathogenicity. PLG is a plausible biological candidate for MS owing to its involvement in immune system response, blood-brain barrier permeability, and myelin degradation. Moreover, components of its activation cascade have been shown to present increased activity or expression in MS patients compared to controls; further studies are needed to clarify whether PLG is involved in MS susceptibility.}, language = {en} } @article{ButtmannSeuffertMaederetal.2016, author = {Buttmann, Mathias and Seuffert, Linda and M{\"a}der, Uwe and Toyka, Klaus V.}, title = {Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study}, series = {Neurology}, volume = {86}, journal = {Neurology}, doi = {10.1212/WNL.0000000000002745}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-188300}, pages = {2203-2207}, year = {2016}, abstract = {Objective: To assess the therapy-related risk of malignancies in mitoxantrone-treated patients with multiple sclerosis. Methods: This retrospective observational cohort study included all mitoxantrone-treated patients with multiple sclerosis seen at our department between 1994 and 2007. We collected follow-up information on medically confirmed malignancies, life status, and cause of death, as of 2010. Malignancy rates were compared to the German national cancer registry matched for sex, age, and year of occurrence. Results: Follow-up was completed in 676 of 677 identified patients. Median follow-up time was 8.7 years (interquartile range 6.8-11.2), corresponding to 6,220 person-years. Median cumulative mitoxantrone dose was 79.0 mg/m(2) (interquartile range 50.8-102.4). Thirty-seven patients (5.5\%) were diagnosed with a malignancy after mitoxantrone initiation, revealing a standardized incidence ratio of 1.50 (95\% confidence interval CI] 1.05-2.08). Entities included breast cancer (n = 9), colorectal cancer (n = 7), acute myeloid leukemia (n = 4, 0.6\%), and others (each entity n = 1 or 2). The standardized incidence ratio of colorectal cancer was 2.98 (95\% CI 1.20-6.14) and of acute myeloid leukemia 10.44 (95\% CI 3.39-24.36). It was not increased for other entities including breast cancer. Multivariate Cox regression identified higher age at treatment initiation but neither cumulative mitoxantrone dose (>75 vs 75 mg/m(2)) nor treatment with other immunosuppressive drugs or sex as a risk factor. Fifty-five patients had died, among them 12 of a malignancy and 43 reportedly of other causes. Conclusions: While the overall incidence of malignancies was only mildly increased, the risk of leukemia and colorectal cancer was heightened. If confirmed, posttherapy colonoscopy could become advisable.}, language = {en} } @phdthesis{Schampel2017, author = {Schampel, Andrea}, title = {Beneficial therapeutic effects of the L-type calcium channel antagonist nimodipine in experimental autoimmune encephalomyelitis - an animal model for multiple sclerosis}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-148952}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2017}, abstract = {Multiple sclerosis (MS) is the most prevalent neurological disease of the central nervous system (CNS) in young adults and is characterized by inflammation, demyelination and axonal pathology that result in multiple neurological and cognitive deficits. The focus of MS research remains on modulating the immune response, but common therapeutic strategies are only effective in slowing down disease progression and attenuating the symptoms; they cannot cure the disease. Developing an option to prevent neurodegeneration early on would be a valuable addition to the current standard of care for MS. Based on our results we suggest that application of nimodipine could be an effective way to target both neuroinflammation and neurodegeneration. We performed detailed analyses of neurodegeneration in experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and in in vitro experiments regarding the effect of the clinically well-established L-type calcium channel antagonist nimodipine. Nimodipine treatment attenuated the course of EAE and spinal cord histopathology. Furthermore, it promoted remyelination. The latter could be due to the protective effect on oligodendrocytes and oligodendrocyte precursor cells (OPCs) we observed in response to nimodipine treatment. To our surprise, we detected calcium channel-independent effects on microglia, resulting in apoptosis. These effects were cell type-specific and independent of microglia polarization. Apoptosis was accompanied by decreased levels of nitric oxide (NO) and inducible NO synthase (iNOS) in cell culture as well as decreased iNOS expression and reactive oxygen species (ROS) activity in EAE. Overall, application of nimodipine seems to generate a favorable environment for regenerative processes and could therefore be a novel treatment option for MS, combining immunomodulatory effects while promoting neuroregeneration.}, subject = {Nimodipin}, language = {en} } @article{BailNotzRovitusoetal.2017, author = {Bail, Kathrin and Notz, Quirin and Rovituso, Damiano M. and Schampel, Andrea and Wunsch, Marie and Koeniger, Tobias and Schropp, Verena and Bharti, Richa and Scholz, Claus-Juergen and Foerstner, Konrad U. and Kleinschnitz, Christoph and Kuerten, Stefanie}, title = {Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.}, series = {Journal of Neuroinflammation}, volume = {14}, journal = {Journal of Neuroinflammation}, number = {148}, doi = {10.1186/s12974-017-0924-4}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-157869}, year = {2017}, abstract = {Background: MP4-induced experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis (MS), which enables targeted research on B cells, currently much discussed protagonists in MS pathogenesis. Here, we used this model to study the impact of the S1P1 receptor modulator FTY720 (fingolimod) on the autoreactive B cell and antibody response both in the periphery and the central nervous system (CNS). Methods: MP4-immunized mice were treated orally with FTY720 for 30 days at the peak of disease or 50 days after EAE onset. The subsequent disease course was monitored and the MP4-specific B cell/antibody response was measured by ELISPOT and ELISA. RNA sequencing was performed to determine any effects on B cell-relevant gene expression. S1P\(_{1}\) receptor expression by peripheral T and B cells, B cell subset distribution in the spleen and B cell infiltration into the CNS were studied by flow cytometry. The formation of B cell aggregates and of tertiary lymphoid organs (TLOs) was evaluated by histology and immunohistochemistry. Potential direct effects of FTY720 on B cell aggregation were studied in vitro. Results: FTY720 significantly attenuated clinical EAE when treatment was initiated at the peak of EAE. While there was a significant reduction in the number of T cells in the blood after FTY720 treatment, B cells were only slightly diminished. Yet, there was evidence for the modulation of B cell receptor-mediated signaling upon FTY720 treatment. In addition, we detected a significant increase in the percentage of B220\(^{+}\) B cells in the spleen both in acute and chronic EAE. Whereas acute treatment completely abrogated B cell aggregate formation in the CNS, the numbers of infiltrating B cells and plasma cells were comparable between vehicle- and FTY720-treated mice. In addition, there was no effect on already developed aggregates in chronic EAE. In vitro B cell aggregation assays suggested the absence of a direct effect of FTY720 on B cell aggregation. However, FTY720 impacted the evolution of B cell aggregates into TLOs. Conclusions: The data suggest differential effects of FTY720 on the B cell compartment in MP4-induced EAE.}, language = {en} } @article{KolbMaeurerSunderkoetterKukowskietal.2019, author = {Kolb-M{\"a}urer, Annette and Sunderk{\"o}tter, Cord and Kukowski, Borries and Meuth, Sven G.}, title = {An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists}, series = {BMC Neurology}, volume = {19}, journal = {BMC Neurology}, doi = {10.1186/s12883-019-1354-y}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-224646}, year = {2019}, abstract = {Background: Interferon (IFN) beta drugs have been approved for the treatment of relapsing forms of multiple sclerosis (RMS) for more than 20years and are considered to offer a favourable benefit-risk profile. In July 2014, subcutaneous (SC) peginterferon beta-1a 125g dosed every 2weeks, a pegylated form of interferon beta-1a, was approved by the EMA for the treatment of adult patients with RRMS and in August 2014 by the FDA for RMS. Peginterferon beta-1a shows a prolonged half-life and increased systemic drug exposure resulting in a reduced dosing frequency compared to other available interferon-based products in MS. In the Phase 3 ADVANCE trial peginterferon beta-1a demonstrated significant positive effects on clinical and MRI outcome measures versus placebo after one year. Furthermore, in the ATTAIN extension study, sustained efficacy with long-term treatment for nearly 6years was shown. Main text In July 2016, an interdisciplinary panel of German and Austrian experts convened to discuss the management of side effects associated with peginterferon beta-1a and other interferon beta-based treatments in MS in daily practice. The panel was composed of experts from university hospitals and private clinics comprised of neurologists, dermatologists, and an MS nurse. In this paper we report recommendations regarding best practices for adverse event management, focussing on peginterferon beta-1a. Injection site reactions (ISRs) and influenza-like illness are the most common adverse effects of interferon beta therapies and can present a burden for MS patients leading to non-adherence and discontinuation of therapy. Peginterferon beta-1a shows improved pharmacological properties. In clinical trials, the adverse event (AE) profile of peginterferon beta-1a was similar to other interferon beta formulations. The most common AEs were mild to moderate ISRs, influenza-like illness, pyrexia, and headache. Current information on the underlying cause of skin reactions associated with SC interferon treatment, and the management strategies for these AEs are limited. In pivotal trials, ISRs were mainly characterized and classified by neurologists, while dermatologists were only rarely consulted. Conclusions This report addresses expert recommendations on the management of most relevant adverse effects related to peginterferon beta-1a and other interferon betas, based on literature and interdisciplinary experience.}, language = {en} } @article{HaarmannSchuhmannSilwedeletal.2019, author = {Haarmann, Axel and Schuhmann, Michael K. and Silwedel, Christine and Monoranu, Camelia-Maria and Stoll, Guido and Buttmann, Mathias}, title = {Human brain endothelial CXCR2 is inflammation-inducible and mediates CXCL5- and CXCL8-triggered paraendothelial barrier breakdown}, series = {International Journal of Molecular Science}, volume = {20}, journal = {International Journal of Molecular Science}, number = {3}, issn = {1422-0067}, doi = {10.3390/ijms20030602}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201297}, year = {2019}, abstract = {Chemokines (C-X-C) motif ligand (CXCL) 5 and 8 are overexpressed in patients with multiple sclerosis, where CXCL5 serum levels were shown to correlate with blood-brain barrier dysfunction as evidenced by gadolinium-enhanced magnetic resonance imaging. Here, we studied the potential role of CXCL5/CXCL8 receptor 2 (CXCR2) as a regulator of paraendothelial brain barrier function, using the well-characterized human cerebral microvascular endothelial cell line hCMEC/D3. Low basal CXCR2 mRNA and protein expression levels in hCMEC/D3 were found to strongly increase under inflammatory conditions. Correspondingly, immunohistochemistry of brain biopsies from two patients with active multiple sclerosis revealed upregulation of endothelial CXCR2 compared to healthy control tissue. Recombinant CXCL5 or CXCL8 rapidly and transiently activated Akt/protein kinase B in hCMEC/D3. This was followed by a redistribution of tight junction-associated protein zonula occludens-1 (ZO-1) and by the formation of actin stress fibers. Functionally, these morphological changes corresponded to a decrease of paracellular barrier function, as measured by a real-time electrical impedance-sensing system. Importantly, preincubation with the selective CXCR2 antagonist SB332235 partially prevented chemokine-induced disturbance of both tight junction morphology and function. We conclude that human brain endothelial CXCR2 may contribute to blood-brain barrier disturbance under inflammatory conditions with increased CXCL5 and CXCL8 expression, where CXCR2 may also represent a novel pharmacological target for blood-brain barrier stabilization.}, language = {en} } @article{FlacheneckerBuresGawliketal.2020, author = {Flachenecker, Peter and Bures, Anna Karoline and Gawlik, Angeli and Weiland, Ann-Christin and Kuld, Sarah and Gusowski, Klaus and Streber, Ren{\´e} and Pfeifer, Klaus and Tallner, Alexander}, title = {Efficacy of an internet-based program to promote physical activity and exercise after inpatient rehabilitation in persons with multiple sclerosis: a randomized, single-blind, controlled study}, series = {International Journal of Environmental Research and Public Health}, volume = {17}, journal = {International Journal of Environmental Research and Public Health}, number = {12}, issn = {1660-4601}, doi = {10.3390/ijerph17124544}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-207863}, year = {2020}, abstract = {Background: Multimodal rehabilitation improves fatigue and mobility in persons with multiple sclerosis (PwMS). Effects are transient and may be conserved by internet-based physical activity promotion programs. Objective: Evaluate the effects of internet-based physical activity and exercise promotion on fatigue, quality of life, and gait in PwMS after inpatient rehabilitation. Methods: PwMS (Expanded Disability Status Scale (EDSS) ≤ 6.0, fatigue: W{\"u}rzburg Fatigue Inventory for Multiple Sclerosis (WEIMuS) ≥ 32) were randomized into an intervention group (IG) or a control group (CG). After rehabilitation, IG received 3 months of internet-based physical activity promotion, while CG received no intervention. Primary outcome: self-reported fatigue (WEIMuS). Secondary outcomes: quality of life (Multiple Sclerosis Impact Scale 29, MSIS-29), gait (2min/10m walking test, Tinetti score). Measurements: beginning (T0) and end (T1) of inpatient rehabilitation, 3 (T2) and 6 (T3) months afterwards. Results: 64 of 84 PwMS were analyzed (IG: 34, CG: 30). After rehabilitation, fatigue decreased in both groups. At T2 and T3, fatigue increased again in CG but was improved in IG (p < 0.001). MSIS-29 improved in both groups at T1 but remained improved at T2 and T3 only in IG. Gait improvements were more pronounced in IG at T2. Conclusions: The study provides Class II evidence that the effects of rehabilitation on fatigue, quality of life, and gait can be maintained for 3-6 months with an internet-based physical activity and exercise promotion program.}, language = {en} } @article{GomezFernandezLopezdeLapuentePortillaAstobizaetal.2020, author = {G{\´o}mez-Fern{\´a}ndez, Paloma and Lopez de Lapuente Portilla, Aitzkoa and Astobiza, Ianire and Mena, Jorge and Urtasun, Andoni and Altmann, Vivian and Matesanz, Fuencisla and Otaegui, David and Urcelay, Elena and Antig{\"u}edad, Alfredo and Malhotra, Sunny and Montalban, Xavier and Castillo-Trivi{\~n}o, Tamara and Espino-Pais{\´a}n, Laura and Aktas, Orhan and Buttmann, Mathias and Chan, Andrew and Fontaine, Bertrand and Gourraud, Pierre-Antoine and Hecker, Michael and Hoffjan, Sabine and Kubisch, Christian and K{\"u}mpfel, Tania and Luessi, Felix and Zettl, Uwe K. and Zipp, Frauke and Alloza, Iraide and Comabella, Manuel and Lill, Christina M. and Vandenbroeck, Koen}, title = {The rare IL22RA2 signal peptide coding variant rs28385692 decreases secretion of IL-22BP isoform-1, -2 and -3 and is associated with risk for multiple sclerosis}, series = {Cells}, volume = {9}, journal = {Cells}, number = {1}, issn = {2073-4409}, doi = {10.3390/cells9010175}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-200769}, year = {2020}, abstract = {The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 × 10\(^{-4}\)). Importantly, logistic regression analyses conditioning on the main known MS-associated SNP at this locus, rs17066096, revealed that this association was independent from the primary association signal in the full case-control dataset. In silico analysis predicted both disruption of the alpha helix of the H-region of the SP and decreased hydrophobicity of this region, ultimately affecting the SP cleavage site. We tested the effect of the p.Leu16Pro variant on the secretion of IL-22BPi1, IL-22BPi2 and IL-22BPi3 and observed that the Pro16 risk allele significantly lowers secretion levels of each of the isoforms to around 50\%-60\% in comparison to the Leu16 reference allele. Thus, our study suggests that genetically coded decreased levels of IL-22BP isoforms are associated with augmented risk for MS.}, language = {en} } @article{NguemeniHomolaNakchbandietal.2020, author = {Nguemeni, Carine and Homola, Gy{\"o}rgy A. and Nakchbandi, Luis and Pham, Mirko and Volkmann, Jens and Zeller, Daniel}, title = {A Single Session of Anodal Cerebellar Transcranial Direct Current Stimulation Does Not Induce Facilitation of Locomotor Consolidation in Patients With Multiple Sclerosis}, series = {Frontiers in Human Neuroscience}, volume = {14}, journal = {Frontiers in Human Neuroscience}, issn = {1662-5161}, doi = {10.3389/fnhum.2020.588671}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-215291}, year = {2020}, abstract = {Background: Multiple sclerosis (MS) may cause variable functional impairment. The discrepancy between functional impairment and brain imaging findings in patients with MS (PwMS) might be attributed to differential adaptive and consolidation capacities. Modulating those abilities could contribute to a favorable clinical course of the disease. Objectives: We examined the effect of cerebellar transcranial direct current stimulation (c-tDCS) on locomotor adaptation and consolidation in PwMS using a split-belt treadmill (SBT) paradigm. Methods: 40 PwMS and 30 matched healthy controls performed a locomotor adaptation task on a SBT. First, we assessed locomotor adaptation in PwMS. In a second investigation, this training was followed by cerebellar anodal tDCS applied immediately after the task ipsilateral to the fast leg (T0). The SBT paradigm was repeated 24 h (T1) and 78 h (T2) post-stimulation to evaluate consolidation. Results: The gait dynamics and adaptation on the SBT were comparable between PwMS and controls. We found no effects of offline cerebellar anodal tDCS on locomotor adaptation and consolidation. Participants who received the active stimulation showed the same retention index than sham-stimulated subjects at T1 (p = 0.33) and T2 (p = 0.46). Conclusion: Locomotor adaptation is preserved in people with mild-to-moderate MS. However, cerebellar anodal tDCS applied immediately post-training does not further enhance this ability. Future studies should define the neurobiological substrates of maintained plasticity in PwMS and how these substrates can be manipulated to improve compensation. Systematic assessments of methodological variables for cerebellar tDCS are urgently needed to increase the consistency and replicability of the results across experiments in various settings.}, language = {en} } @article{RiedererterMeulen2020, author = {Riederer, Peter and ter Meulen, Volker}, title = {Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses}, series = {Journal of Neural Transmission}, volume = {127}, journal = {Journal of Neural Transmission}, number = {9}, issn = {0300-9564}, doi = {10.1007/s00702-020-02230-x}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-314637}, pages = {1217-1228}, year = {2020}, abstract = {While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood-brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS-dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis.}, language = {en} } @article{NguemeniHiewKoegleretal.2021, author = {Nguemeni, Carine and Hiew, Shawn and K{\"o}gler, Stefanie and Homola, Gy{\"o}rgy A. and Volkmann, Jens and Zeller, Daniel}, title = {Split-belt training but not cerebellar anodal tDCS improves stability control and reduces risk of fall in patients with multiple sclerosis}, series = {Brain Sciences}, volume = {12}, journal = {Brain Sciences}, number = {1}, issn = {2076-3425}, doi = {10.3390/brainsci12010063}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252179}, year = {2021}, abstract = {The objective of this study was to examine the therapeutic potential of multiple sessions of training on a split-belt treadmill (SBT) combined with cerebellar anodal transcranial direct current stimulation (tDCS) on gait and balance in People with Multiple Sclerosis (PwMS). Twenty-two PwMS received six sessions of anodal (PwMS\(_{real}\), n = 12) or sham (PwMS\(_{sham}\), n = 10) tDCS to the cerebellum prior to performing the locomotor adaptation task on the SBT. To evaluate the effect of the intervention, functional gait assessment (FGA) scores and distance walked in 2 min (2MWT) were measured at the baseline (T0), day 6 (T5), and at the 4-week follow up (T6). Locomotor performance and changes of motor outcomes were similar in PwMS\(_{real}\) and PwMS\(_{sham}\) independently from tDCS mode applied to the cerebellum (anodal vs. sham, on FGA, p = 0.23; and 2MWT, p = 0.49). When the data were pooled across the groups to investigate the effects of multiple sessions of SBT training alone, significant improvement of gait and balance was found on T5 and T6, respectively, relative to baseline (FGA, p < 0.001 for both time points). The FGA change at T6 was significantly higher than at T5 (p = 0.01) underlining a long-lasting improvement. An improvement of the distance walked during the 2MWT was also observed on T5 and T6 relative to T0 (p = 0.002). Multiple sessions of SBT training resulted in a lasting improvement of gait stability and endurance, thus potentially reducing the risk of fall as measured by FGA and 2MWT. Application of cerebellar tDCS during SBT walking had no additional effect on locomotor outcomes.}, language = {en} } @article{RajendranBoettigerDentzienetal.2021, author = {Rajendran, Ranjithkumar and B{\"o}ttiger, Gregor and Dentzien, Niklas and Rajendran, Vinothkumar and Sharifi, Bischand and Erg{\"u}n, S{\"u}leyman and Stadelmann, Christine and Karnati, Srikanth and Berghoff, Martin}, title = {Effects of FGFR tyrosine kinase inhibition in OLN-93 oligodendrocytes}, series = {Cells}, volume = {10}, journal = {Cells}, number = {6}, issn = {2073-4409}, doi = {10.3390/cells10061318}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239600}, year = {2021}, abstract = {Fibroblast growth factor (FGF) signaling is involved in the pathogenesis of multiple sclerosis (MS). Data from neuropathology studies suggest that FGF signaling contributes to the failure of remyelination in MS. In MOG\(_{35-55}\)-induced EAE, oligodendrocyte-specific deletion of FGFR1 and FGFR2 resulted in a less severe disease course, reduced inflammation, myelin and axon degeneration and changed FGF/FGFR and BDNF/TrkB signaling. Since signaling cascades in oligodendrocytes could not be investigated in the EAE studies, we here aimed to characterize FGFR-dependent oligodendrocyte-specific signaling in vitro. FGFR inhibition was achieved by application of the multi-kinase-inhibitor dovitinib and the FGFR1/2/3-inhibitor AZD4547. Both substances are potent inhibitors of FGF signaling; they are effective in experimental tumor models and patients with malignancies. Effects of FGFR inhibition in oligodendrocytes were studied by immunofluorescence microscopy, protein and gene analyses. Application of the tyrosine kinase inhibitors reduced FGFR1, phosphorylated ERK and Akt expression, and it enhanced BDNF and TrkB expression. Furthermore, the myelin proteins CNPase and PLP were upregulated by FGFR inhibition. In summary, inhibition of FGFR signaling in oligodendrocytes can be achieved by application of tyrosine kinase inhibitors. Decreased phosphorylation of ERK and Akt is associated with an upregulation of BDNF/TrkB signaling, which may be responsible for the increased production of myelin proteins. Furthermore, these data suggest that application of FGFR inhibitors may have the potential to promote remyelination in the CNS.}, language = {en} } @article{VogelsangEichlerHuntemannetal.2021, author = {Vogelsang, Anna and Eichler, Susann and Huntemann, Niklas and Masanneck, Lars and B{\"o}hnlein, Hannes and Sch{\"u}ngel, Lisa and Willison, Alice and Loser, Karin and Nieswandt, Bernhard and Kehrel, Beate E. and Zarbock, Alexander and G{\"o}bel, Kerstin and Meuth, Sven G.}, title = {Platelet inhibition by low-dose acetylsalicylic acid reduces neuroinflammation in an animal model of multiple sclerosis}, series = {International Journal of Molecular Sciences}, volume = {22}, journal = {International Journal of Molecular Sciences}, number = {18}, issn = {1422-0067}, doi = {10.3390/ijms22189915}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-284535}, year = {2021}, abstract = {Aside from the established immune-mediated etiology of multiple sclerosis (MS), compelling evidence implicates platelets as important players in disease pathogenesis. Specifically, numerous studies have highlighted that activated platelets promote the central nervous system (CNS)-directed adaptive immune response early in the disease course. Platelets, therefore, present a novel opportunity for modulating the neuroinflammatory process that characterizes MS. We hypothesized that the well-known antiplatelet agent acetylsalicylic acid (ASA) could inhibit neuroinflammation by affecting platelets if applied at low-dose and investigated its effect during experimental autoimmune encephalomyelitis (EAE) as a model to study MS. We found that oral administration of low-dose ASA alleviates symptoms of EAE accompanied by reduced inflammatory infiltrates and less extensive demyelination. Remarkably, the percentage of CNS-infiltrated CD4\(^+\) T cells, the major drivers of neuroinflammation, was decreased to 40.98 ± 3.28\% in ASA-treated mice compared to 56.11 ± 1.46\% in control animals at the disease maximum as revealed by flow cytometry. More interestingly, plasma levels of thromboxane A\(_2\) were decreased, while concentrations of platelet factor 4 and glycoprotein VI were not affected by low-dose ASA treatment. Overall, we demonstrate that low-dose ASA could ameliorate the platelet-dependent neuroinflammatory response in vivo, thus indicating a potential treatment approach for MS.}, language = {en} } @article{WinterKernGalletal.2021, author = {Winter, Carla and Kern, Florian and Gall, Dominik and Latoschik, Marc Erich and Pauli, Paul and K{\"a}thner, Ivo}, title = {Immersive virtual reality during gait rehabilitation increases walking speed and motivation: a usability evaluation with healthy participants and individuals with multiple sclerosis and stroke}, series = {Journal of Neuroengineering and Rehabilitation}, volume = {18}, journal = {Journal of Neuroengineering and Rehabilitation}, number = {1}, issn = {1743-0003}, doi = {10.1186/s12984-021-00848-w}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-258698}, year = {2021}, abstract = {Background: The rehabilitation of gait disorders in patients with multiple sclerosis (MS) and stroke is often based on conventional treadmill training. Virtual reality (VR)-based treadmill training can increase motivation and improve therapy outcomes. The present study evaluated an immersive virtual reality application (using a head-mounted display, HMD) for gait rehabilitation with patients to (1) demonstrate its feasibility and acceptance and to (2) compare its short-term effects to a semi-immersive presentation (using a monitor) and a conventional treadmill training without VR to assess the usability of both systems and estimate the effects on walking speed and motivation. Methods: In a within-subjects study design, 36 healthy participants and 14 persons with MS or stroke participated in each of the three experimental conditions (VR via HMD, VR via monitor, treadmill training without VR). Results: For both groups, the walking speed in the HMD condition was higher than in treadmill training without VR and in the monitor condition. Healthy participants reported a higher motivation after the HMD condition as compared with the other conditions. Importantly, no side effects in the sense of simulator sickness occurred and usability ratings were high. No increases in heart rate were observed following the VR conditions. Presence ratings were higher for the HMD condition compared with the monitor condition for both user groups. Most of the healthy study participants (89\%) and patients (71\%) preferred the HMD-based training among the three conditions and most patients could imagine using it more frequently. Conclusions For the first time, the present study evaluated the usability of an immersive VR system for gait rehabilitation in a direct comparison with a semi-immersive system and a conventional training without VR with healthy participants and patients. The study demonstrated the feasibility of combining a treadmill training with immersive VR. Due to its high usability and low side effects, it might be particularly suited for patients to improve training motivation and training outcome e. g. the walking speed compared with treadmill training using no or only semi-immersive VR. Immersive VR systems still require specific technical setup procedures. This should be taken into account for specific clinical use-cases during a cost-benefit assessment.}, language = {en} } @article{RajendranBoettigerStadelmannetal.2021, author = {Rajendran, Ranjithkumar and B{\"o}ttiger, Gregor and Stadelmann, Christine and Karnati, Srikanth and Berghoff, Martin}, title = {FGF/FGFR pathways in multiple sclerosis and in its disease models}, series = {Cells}, volume = {10}, journal = {Cells}, number = {4}, issn = {2073-4409}, doi = {10.3390/cells10040884}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236594}, year = {2021}, abstract = {Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) affecting more than two million people worldwide. In MS, oligodendrocytes and myelin sheaths are destroyed by autoimmune-mediated inflammation, while remyelination is impaired. Recent investigations of post-mortem tissue suggest that Fibroblast growth factor (FGF) signaling may regulate inflammation and myelination in MS. FGF2 expression seems to correlate positively with macrophages/microglia and negatively with myelination; FGF1 was suggested to promote remyelination. In myelin oligodendrocyte glycoprotein (MOG)\(_{35-55}\)-induced experimental autoimmune encephalomyelitis (EAE), systemic deletion of FGF2 suggested that FGF2 may promote remyelination. Specific deletion of FGF receptors (FGFRs) in oligodendrocytes in this EAE model resulted in a decrease of lymphocyte and macrophage/microglia infiltration as well as myelin and axon degeneration. These effects were mediated by ERK/Akt phosphorylation, a brain-derived neurotrophic factor, and downregulation of inhibitors of remyelination. In the first part of this review, the most important pharmacotherapeutic principles for MS will be illustrated, and then we will review recent advances made on FGF signaling in MS. Thus, we will suggest application of FGFR inhibitors, which are currently used in Phase II and III cancer trials, as a therapeutic option to reduce inflammation and induce remyelination in EAE and eventually MS.}, language = {en} } @article{KamaliRajendranStadelmannetal.2021, author = {Kamali, Salar and Rajendran, Ranjithkumar and Stadelmann, Christine and Karnati, Srikanth and Rajendran, Vinothkumar and Giraldo-Velasquez, Mario and Berghoff, Martin}, title = {Oligodendrocyte-specific deletion of FGFR2 ameliorates MOG\(_{35-55}\)-induced EAE through ERK and Akt signalling}, series = {Brain Pathology}, volume = {31}, journal = {Brain Pathology}, doi = {10.1111/bpa.12916}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-224354}, pages = {297 -- 311}, year = {2021}, abstract = {Fibroblast growth factors (FGFs) and their receptors (FGFRs) are involved in demyelinating pathologies including multiple sclerosis (MS). In our recent study, oligodendrocyte-specific deletion of FGFR1 resulted in a milder disease course, less inflammation, reduced myelin and axon damage in EAE. The objective of this study was to elucidate the role of oligodendroglial FGFR2 in MOG\(_{35-55}\)-induced EAE. Oligodendrocyte-specific knockout of FGFR2 (Fgfr2\(^{ind-/-}\)) was achieved by application of tamoxifen; EAE was induced using the MOG\(_{35-55}\) peptide. EAE symptoms were monitored over 62 days. Spinal cord tissue was analysed by histology, immunohistochemistry and western blot. Fgfr2\(^{ind-/-}\) mice revealed a milder disease course, less myelin damage and enhanced axonal density. The number of oligodendrocytes was not affected in demyelinated areas. However, protein expression of FGFR2, FGF2 and FGF9 was downregulated in Fgfr2\(^{ind-/-}\) mice. FGF/FGFR dependent signalling proteins were differentially regulated; pAkt was upregulated and pERK was downregulated in Fgfr2\(^{ind-/-}\) mice. The number of CD3(+) T cells, Mac3(+) cells and B220(+) B cells was less in demyelinated lesions of Fgfr2\(^{ind-/-}\) mice. Furthermore, expression of IL-1β, TNF-α and CD200 was less in Fgfr2\(^{ind-/-}\) mice than controls. Fgfr2ind-/- mice showed an upregulation of PLP and downregulation of the remyelination inhibitors SEMA3A and TGF-β expression. These data suggest that cell-specific deletion of FGFR2 in oligodendrocytes has anti-inflammatory and neuroprotective effects accompanied by changes in FGF/FGFR dependent signalling, inflammatory cytokines and expression of remyelination inhibitors. Thus, FGFRs in oligodendrocytes may represent potential targets for the treatment of inflammatory and demyelinating diseases including MS.}, language = {en} } @phdthesis{Nakchbandi2022, author = {Nakchbandi, Luis}, title = {Adaptives motorisches Lernen und seine Konsolidierung bei Multipler Sklerose}, doi = {10.25972/OPUS-25246}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-252465}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2022}, abstract = {Der Verlauf der Multiplen Sklerose ist heterogener Natur; die F{\"a}higkeit zu einem intakten adaptiven motorischen Lernen und einer intakten Konsolidierung k{\"o}nnten einen milden Krankheitsverlauf beg{\"u}nstigen. In der vorliegenden Arbeit wurden das adaptive motorische Lernen und seine Konsolidierung bei MS-Patienten im Vergleich zu neurologisch gesunden Kontrollprobanden untersucht; außerdem wurde das Verh{\"a}ltnis dieser Formen des Lernens zu klinischen und apparativen Parametern des Krankheitsprogresses untersucht. Dazu f{\"u}hrten 20 MS-Patienten und 20 Kontrollprobanden eine visuoadaptive Lernaufgabe durch. Hierzu sollten mittels Computerbildschirm und Computermaus geradlinige Zielbewegungen zwischen einem Startpunkt und einem Zielpunkt wechselnder Lokalisation durchgef{\"u}hrt werden, wobei in einem Rotationsmodus eine externe Ablenkung der Zielbewegung im Uhrzeigersinn eingef{\"u}hrt wurde, welche auszugleichen war. Die {\"U}bungssitzung wurde nach 24 Stunden und nach 72 Stunden wiederholt. Analysiert wurden die Richtungsfehler der Zielbewegungen, die Adaptationsrate an die Ablenkung und die Retention der erlernten Adaptation bis zur Folgesitzung. Motorische Einschr{\"a}nkung wurde durch den EDSS-Score und den 9-Loch-Stecktest quantifiziert, zentralnerv{\"o}se L{\"a}sionslast wurde mittels cMRT und MEP ermittelt. Die Adaptation und Lernf{\"a}higkeit innerhalb einer {\"U}bungssitzung waren in der Patienten- und der Kontrollgruppe vergleichbar; jedoch zeigte sich eine signifikant verminderte Retentionsrate in der Patientengruppe an den Folgeuntersuchungstagen im Vergleich zur Kontrollgruppe. In den Korrelationsanalysen und Subgruppenvergleichen innerhalb der Patientengruppe nach Stratifizierung aufgrund von EDSS-Score, 9-Lochstecktest und zentralnerv{\"o}ser L{\"a}sionslast im MRT konnte kein eindeutiger Zusammenhang zwischen klinischer Beeintr{\"a}chtigung bzw. zentralnerv{\"o}ser L{\"a}sionslast auf der einen Seite und Adaptation bzw. Konsolidierung auf der anderen Seite identifiziert werden. Jedoch zeigte sich in der Patientengruppe f{\"u}r den ersten Nachuntersuchungstag eine signifikant h{\"o}here Retentionsrate in der Subgruppe mit geringerer Leistung im 9-Lochsteck-Test. Insgesamt deuten die vorliegenden Daten auf eine erhaltene F{\"a}higkeit zu adaptivem motorischen Lernen und somit auf eine erhaltene rasch einsetzende Neuroplastizit{\"a}t bei leicht bis mittelgradig betroffenen MS-Patienten hin; jedoch sprechen die Daten f{\"u}r eine eingeschr{\"a}nkte Konsolidierungsf{\"a}higkeit. Zentralnerv{\"o}se L{\"a}sionslast scheint Motoradaptation und Konsolidierung nicht zu verhindern. Das genaue Verh{\"a}ltnis der Motoradapation und Konsolidierung zum klinischen Funktionserhalt konnte nicht genauer aufgekl{\"a}rt werden. Um die genaue Beziehung zwischen Motoradaptation und Konsolidierung und klinischer Beeintr{\"a}chtigung bzw. ZNS-L{\"a}sionen zu eruieren, bedarf es weiterer Studien.}, subject = {Multiple Sklerose}, language = {de} } @article{HiewNguemeniZeller2022, author = {Hiew, Shawn and Nguemeni, Carine and Zeller, Daniel}, title = {Efficacy of transcranial direct current stimulation in people with multiple sclerosis: a review}, series = {European Journal of Neurology}, volume = {29}, journal = {European Journal of Neurology}, number = {2}, doi = {10.1111/ene.15163}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-259424}, pages = {648-664}, year = {2022}, abstract = {Background and purpose Multiple sclerosis (MS) is a chronic inflammatory disease causing a wide range of symptoms including motor and cognitive impairment, fatigue and pain. Over the last two decades, non-invasive brain stimulation, especially transcranial direct current stimulation (tDCS), has increasingly been used to modulate brain function in various physiological and pathological conditions. However, its experimental applications for people with MS were noted only as recently as 2010 and have been growing since then. The efficacy for use in people with MS remains questionable with the results of existing studies being largely conflicting. Hence, the aim of this review is to paint a picture of the current state of tDCS in MS research grounded on studies applying tDCS that have been done to date. Methods A keyword search was performed to retrieve articles from the earliest article identified until 14 February 2021 using a combination of the groups (1) 'multiple sclerosis', 'MS' and 'encephalomyelitis' and (2) 'tDCS' and 'transcranial direct current stimulation'. Results The analysis of the 30 articles included in this review underlined inconsistent effects of tDCS on the motor symptoms of MS based on small sample sizes. However, tDCS showed promising benefits in ameliorating fatigue, pain and cognitive symptoms. Conclusion Transcranial direct current stimulation is attractive as a non-drug approach in ameliorating MS symptoms, where other treatment options remain limited. The development of protocols tailored to the individual's own neuroanatomy using high definition tDCS and the introduction of network mapping in the experimental designs might help to overcome the variability between studies.}, language = {en} } @article{RajendranRajendranGuptaetal.2022, author = {Rajendran, Ranjithkumar and Rajendran, Vinothkumar and Gupta, Liza and Shirvanchi, Kian and Schunin, Darja and Karnati, Srikanth and Giraldo-Vel{\´a}squez, Mario and Berghoff, Martin}, title = {Interferon beta-1a versus combined interferon beta-1a and oligodendrocyte-specific FGFR1 deletion in experimental autoimmune encephalomyelitis}, series = {International Journal of Molecular Sciences}, volume = {23}, journal = {International Journal of Molecular Sciences}, number = {20}, issn = {1422-0067}, doi = {10.3390/ijms232012183}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290401}, year = {2022}, abstract = {Recombinant beta interferons-1 (IFNβ-1) are used as first line therapies in patients with relapsing multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the CNS. IFNβ-1a/b has moderate effects on the prevention of relapses and slowing of disease progression. Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) are known to play a key role in the pathology of MS and its model EAE. To investigate the effects of short-term treatment with s.c. IFNβ-1a versus the combined application of s.c. IFNβ-1a and oligodendrocyte-specific deletion of FGFR1 (Fgfr1\(^{ind-/-}\) mice) in MOG\(_{35-55}\)-induced EAE. IFNβ-1a (30 mg/kg) was applied s.c. from days 0-7 p.i. of EAE in controls and Fgfr1\(^{ind-/-}\) mice. FGFR signaling proteins associated with inflammation/degeneration in MS/EAE were analyzed by western blot in the spinal cord. Further, FGFR1 in Oli-neu oligodendrocytes were inhibited by PD166866 and treated with IFNβ-1a (400 ng/mL). Application of IFNβ-1a over 8 days resulted in less symptoms only at the peak of disease (days 9-11) compared to controls. Application of IFNβ-1a in Fgfr1\(^{ind-/-}\) mice resulted in less symptoms primarily in the chronic phase of EAE. Fgfr1\(^{ind-/-}\) mice treated with IFNβ-1a showed increased expression of pERK and BDNF. In Oli-neu oligodendrocytes, treatment with PD166866 and IFNβ-1a also showed an increased expression of pERK and BDNF/TrkB. These data suggest that the beneficial effects in the chronic phase of EAE and on signaling molecules associated with ERK and BDNF expression are caused by the modulation of FGFR1 and not by interferon beta-1a. FGFR may be a potential target for therapy in MS.}, language = {en} }